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ABSTRACT 
Pancreatic endocrine progenitors obtained from human embryonic stem cells (hESCs) could be 
used as an alternative source to develop cell-based therapies for diabetes mellitus (DM). 
However, in human a true endocrine progenitor has not been isolated yet. Therefore, the aim of 
our study is to investigate whether it is possible to isolate pancreatic endocrine progenitors from 
differentiating hESC cultures by lineage tracing of NGN3, a known marker of mouse pancreatic 
endocrine progenitors. We targeted the 3’ end of NGN3 using zinc finger nuclease-mediated 
homologous recombination to allow selection of NGN3eGFP+ cells from hESCs differentiating 
towards a pancreatic fate without disrupting the NGN3 gene. These NGN3eGFP+ cells express 
PDX1, NKX6.1 and chromogranin A, and differentiate in vivo towards insulin, glucagon and 
somatostatin single hormone-expressing cells, but not to ductal or exocrine pancreatic cells or 
other endodermal, mesodermal or ectodermal lineages, confirming our hypothesis that NGN3+ 
cells represent pancreatic endocrine progenitors in human. Overall, this hESC reporter line can 
aid in gaining insights in developmental mechanisms underlying fate choices in human pancreas 
as well as in generating cell-based therapies. 
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SAMENVATTING 
Het gebruik van pluripotente stamcellen voor de regeneratieve geneeskunde is veelbelovend, 
omdat deze cellen voorzien zijn van enorm potentieel voor celtherapie alsook voor het 
onderzoeken van de ontwikkeling van organen en ziektes zoals diabetes mellitus (DM) type 1. 
Een ziekte dat wordt gekenmerkt door een verhoogde glucoseconcentratie in het bloed, te wijten 
aan de afwezigheid van β-cellen in de pancreas. Deze cellen zouden kunnen vervangen worden 
door β-cellen afkomstig van gedifferentieerde pluripotente stamcellen. Op deze manier, zouden 
patiënten kunnen verlicht worden van hun dagelijkse insuline-injecties. De meeste studies waarin 
pluripotente stamcellen worden gebruikt voor het genereren van β-cellen maken gebruik van 
gemengde of verrijkte celpopulaties. In die zin, is het moeilijk af te leiden welke cel werkelijk 
bijdraagt tot de gewenste β-cellen. Daarom is een betrouwbare en nauwkeurige techniek nodig 
voor het nagaan welke cellen verantwoordelijk zijn voor het genereren van de cellen van de 
eilandjes van Langerhans. Hiervoor maakten we de hypothese, dat het mogelijk is om humane 
endocriene pancreas voorlopercellen te selecteren door middel van de specifieke selectie van 
neurogenin-3 (NGN3) expresserende cellen afkomstig van gedifferentieerde humane embryonale 
stamcellen (hESC). Een alternatieve bron voor β-cellen zou op deze manier kunnen gegenereerd 
worden. In de muis werd al aangetoond dat Ngn3-expresserende cellen kunnen differentiëren 
naar alle pancreatisch endocriene cellen: α-, β-, δ-, ε- and PP-cellen. Daarom is Ngn3 een nuttige 
merker voor cellen die van een progenitorrol verder differentiëren naar een meer matuur 
endocriene rol. Om de selectie van Ngn3-expresserende cellen mogelijk te maken, hebben we 
gebruik gemaakt van de “zinc finger nuclease” (ZFN) gemedieerde homologe recombinatie (HR) 
technologie voor het genereren van hESC lijnen waarbij een fluorochroom tot expressie komt, 
wanneer NGN3 wordt geïnduceerd. Dit gebeurt zonder dat de coderende sequentie van het 
NGN3 gen wordt aangepast. Dankzij de differentiatie van deze reporterlijnen was het mogelijk 
om >90% zuivere NGN3eGFP+ cellen te isoleren. Na transplantatie (zonder voorafgaande 
celkweek) van deze opgezuiverde humane NGN3eGFP+ cellen onder het nierkapsel van gezonde 
muizen, konden we de cellen verder differentiëren in pancreatisch endocriene cellen, 
meerbepaald in insuline-, glucagon- en somatostatine-expresserende cellen. Dit is bijgevolg het 
eerste gedetailleerde verslag van een knock-in add-on in een gen, dat niet tot expressie komt in 
hESC. Deze gegenereerde cellijn is uitermate geschikt voor “lineage tracing” studies, die kunnen 
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helpen bij het verkrijgen van meer inzicht in ontwikkelingsmechanismen, die aan de basis liggen 
van celkeuze beslissingen alsook voor het genereren van celgebaseerde therapieën. 
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SUMMARY 
The use of pluripotent stem cells for regenerative medicine holds great promise, because these 
cells are foreseen to have a tremendous potential in cell-replacement therapies as well as in 
elucidating developmental and disease pathways. Therefore a lot of effort has been put in 
exploring their ability to treat diabetes mellitus (DM) type 1, which is characterized by elevated 
blood glucose levels due to the absence of β-cells in the pancreas. Replacing these β-cells with 
pluripotent stem cell-derived β-cells could relief the patient from his daily insulin injections. 
Most studies using pluripotent stem cells for recreating β-cells directly or through the generation 
of pancreatic progenitors rely on the transplantation of mixed or enriched cell populations. In this 
sense, the understanding of which cell contributes to the derivation of the desired β-cells remains 
unclear. Therefore, a reliable and precise tool is needed to track the cells responsible for 
regenerating pancreatic islet cells. For this purpose, we hypothesized that it might be possible to 
select pancreatic endocrine progenitors by specific selection of neurogenin-3 (NGN3)-expressing 
cells from differentiating hESCs which could be used as an alternative cell source to generate β-
cells. In the mouse, Ngn3 expressing cells are known to give rise to all hormone-secreting 
pancreatic endocrine cell types. Therefore, Ngn3 should be a useful marker for cells that are 
transitioning from a pancreatic epithelial progenitor cell fate to an endocrine progenitor cell fate. 
In this light, we made use of the zinc-finger nuclease (ZFN) mediated homologous 
recombination (HR) technology to generate hESC lines wherein a drug resistance and 
fluorochrome selectable cassette has been knocked in using at the 3’end of the NGN3 locus, 
without disrupting the coding sequence of the NGN3 gene. Differentiating these targeted hESCs 
made it possible to select for >90% pure NGN3+ cells from mixed hESC progeny. Upon 
transplantation (without pre-cultivation) of these purified human NGN3+ cells under the kidney 
capsule of healthy mice, we could direct these cells further towards endocrine hormone-
expressing cells, more specifically to insulin, glucagon or somatostatin expressing cells. This 
represents the first detailed report of a knock-in add-on into a non-expressed gene in hESCs 
suitable for lineage tracing studies, which can aid in gaining insights in developmental 
mechanisms underlying fate choices as well as in generating cell-based therapies.  
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1 INTRODUCTION 
 
The term diabetes mellitus (DM) has both Greek and Latin roots. Diabetes originates from the 
Greek word for siphon, alluding to one of the symptoms of the disease concerning the excessive 
water intake which is immediately lost as if it had run through a water pipe, while Mellitus is 
Latin for honey, describing the sweet taste of diabetic urine. The disease, DM, was described for 
the first time in the 3rd century BC by the Greek physician, Demetrius of Apameia, and it was not 
until 1922 that the first patient was treated with insulin1.  
DM which previously has been linked to rich nations has now evolved towards a pandemic. The 
International Diabetes Federation estimates that by 2030 approximately 366 million people 
worldwide will be suffering of DM. DM is characterized by continued elevated levels of blood 
glucose either due to the loss of insulin producing β−cells in the pancreas (type 1), or due to 
decreased sensitivity to insulin (type 2)2. Type 1 DM can be treated with insulin injections to 
normalize blood glucose levels. However, patients still suffer from hyper- and hypoglycemia 
with life-threatening complications such as myocardial infarcts, peripheral limb ischemia and 
stroke. Novel routes of insulin administration e.g. intranasal administration, inhaled insulin, 
gastrointestinal delivery are being examined3. For patients with type 1 DM, and to a lesser extent 
for type 2 DM, the only curative therapy is replacement of lost β−cells by grafting whole 
pancreas or islets4. However, as several cadaveric pancreata are needed to obtain sufficient islets 
to treat a single patient, shortage of donor pancreata prevents the use of this therapy in large 
groups of patients. In addition, although islet grafts can control the glycemia of patients for a 
period of a few years, loss of the graft with time may necessitate the transplantation of islets on 
multiple occasions5. Hence the need for alternative, and if possible renewable, sources of 
β−cells. 
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1.1 Diabetes Mellitus 
a. Description 
β-cells play a pivotal role in controlling blood glucose homeostasis. Most of the food we 
consume is broken down or metabolized into the monosaccharide glucose. The body utilizes 
glucose as the main source of fuel. After digestion of food, glucose enters into the bloodstream, 
where it is used by cells to sustain proliferation and metabolic functions. In order for glucose to 
enter into cells, insulin is required. Insulin is a hormone produced by the pancreas, a large gland 
located behind the stomach. When we eat, the appropriate amount of insulin is normally 
produced by the pancreas in order to move glucose from the blood into cells. However, people 
with DM have problems either with insulin production or insulin resistance (i.e. cells are 
incapable of reacting to the insulin that is produced). As a consequence, the glucose 
concentration in the blood rises (hyperglycemia), and is excreted in the urine. Thus, large 
concentrations of glucose cannot be used as a source of fuel for the body, and the body starts to 
use fat to support cell metabolism and proliferation. Breakdown of fat tissue results in the 
production of ketones, and ketoacidosis is often seen in patients with untreated DM and 
hyperglycemia6. Therefore, DM is described as a metabolic disorder of multiple etiologies that is 
characterized by continually elevated levels of blood glucose or by transitory inadequate 
utilization of ingested glucose. DM can be distinguished from the pre-diabetic states, impaired 
glucose tolerance (IGT) and impaired fasting glucose (IFG). DM is caused by absolute or 
relative insulin deficiency. This disease has many health complications, including coronary heart 
disease, stroke, peripheral vascular disease, blindness, and kidney disease among others2. 
 
b. Types of diabetes mellitus 
DM can be classified into four major groups: type 1 DM, type 2 DM, gestational DM and other 
types (Table 1). Type 1 arises from selective, irreversible destruction of insulin-producing 
pancreatic β-cells. There are two sub-types of type 1 DM: immune-mediated type 1A DM and 
idiopathic type 1B. Type 1A DM is characterized by the fact that the immune system attacks and 
destroys the insulin-producing β-cells in the pancreas. The pancreas then produces little or no 
insulin. Type 1B DM has no known etiologies and is idiopathic. This form of DM is strongly 
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inherited, but currently lacks immunological evidence for β-cell autoimmunity. A patient with 
type 1 DM must take insulin daily to live2, 7. 
The most common form of DM is type 2 DM. This form of DM is most often associated with 
older age, obesity, family history of gestational DM, physical inactivity, and certain ethnicities. 
Type 2 DM is characterized by insulin resistance, where insulin is not efficiently used or is 
produced in insufficient amounts6. Unlike type 1 DM, which always requires insulin therapy, 
type 2 DM treatment options include behavioral modification and administration of various oral 
anti-diabetic agents2. 
The third form of diabetes is called gestational diabetes mellitus (GDM) and usually manifests 
itself in the third trimester of pregnancy 2. GDM is defined as any degree of glucose intolerance 
with onset or first recognition during pregnancy. In the majority of cases of GDM, glucose 
regulation will return to normal after delivery7. 
Other types of DM, reported by the Expert Committee on the diagnosis and classification of DM 
include less common types of largely unknown etiology2, 7. For example, maturity-onset diabetes 
of the young (MODY) are caused by genetic defects in the genes encoding one of the 
transcription factors HNF4α, HNF1α, HNF1β, PDX1 and GLUCOKINASE. This heterogeneous 
subgroup affects approximately 2% of all diabetic patients and affects 2-5% of patients already 
diagnosed with type-2 DM. Identification of the genetic basis for this type of DM has provided 
not only valuable information into the pathology of those afflicted, but has also increased our 
basic understanding of glucose homeostasis and has defined potential therapeutic targets2, 8. 
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Table 1 Etiologic classification of DM, adapted from Gavin et al. 2003. 
I. Type 1 DM* (β-cell destruction, usually leading to absolute insulin deficiency) 
 A. Immune mediated 
 B. Idiopathic 
II. Type 2 DM* (may range from predominantly insulin resistance with relative insulin deficiency to a predominantly 
secretory defect with insulin resistance) 
III. Gestational diabetes mellitus (GDM) 
VI. Other specific types 
 A. Genetic defects of β-cell function 
 B. Genetic defects in insulin action 
 C. Diseases of the exocrine pancreas 
 D. Endocrinopathies 
 E. Drug- or chemical-induced 
 F. Infections 
 G. Uncommon forms of immune-mediated DM 
 H. Other genetic syndromes sometimes associated with DM 
*Patients with any form of DM may require insulin treatment at some stage of their disease. Such use of 
insulin does not, of itself, classify the patient. 
 
c. Symptoms and complications 
Symptoms of type 1 DM usually develop over a short period, although β-cell destruction can 
begin years earlier. Symptoms may include increased thirst and urination, constant hunger, 
weight loss, blurred vision and extreme fatigue. If not diagnosed and treated with insulin, a 
person with type 1 DM can lapse into a life-threatening diabetic coma, also known as diabetic 
ketoacidosis. The symptoms of type 2 DM develop gradually. Symptoms may include fatigue, 
frequent urination, increased thirst and hunger, weight loss, blurred vision, and slow healing of 
wounds. Some people have no symptoms6. 
Several complications are known to be caused by DM: microvascular complication, 
macrovascular complications, diabetic foot disorder and dermatologic disorders. Microvascular 
complications include: retinopathy, nephropathy and neuropathy. A continuous relation exists 
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between glycemic control and the incidence and progression of microvascular complications9, 10. 
A subset of patients with DM suffers from macrovascular complications such as atherosclerotic 
disease with death as a consequence. Important risk factors for atheromatous large vessel disease 
in patients with DM are e.g. smoking, elevated blood pressure, proteinuria, and elevated 
cholesterol levels. Hypertension affects at least half of the patients with DM and as a 
consequence, these patients will eventually suffer from coronary heart disease, peripheral 
vascular disease, stroke, and/or erectile dysfunction9. Foot disorders are a major source of 
morbidity and a leading cause of hospitalization for patients with DM. Significant complications 
of the disease are ulceration, infection, gangrene, and amputation. Charcot foot, which in itself 
can lead to limb-threatening disorders, is another serious complication of long-standing DM11. It 
is estimated that up to 70% of DM suffer from pathologic skin changes during the course of the 
disease. Onset can already occur in patients with pre-DM (IGT and IFG). No skin disease is 
specific to DM2. 
 
d. Treatment of diabetes 
Type 1 diabetes 
The treatment of patients with type 1 DM is currently limited to insulin injections. Conventional 
insulin is of porcine or bovine origin, but use of these insulins is associated with eventual 
immune reactions against the xenogeneic protein resulting in insufficient absorption, and delayed 
and decreased blood peak levels. Most of the types of conventional insulin have now been 
replaced by recombinant human insulin. Several forms of insulin exist: short-acting, 
intermediate-acting and long-acting insulin analogs. Novel routes of insulin therapy are being 
developed to help overcome the practical difficulties of working with injection needles, such as 
intranasal administration, inhaled insulin, and gastrointestinal delivery3. 
 
Type 2 DM 
Type 1 DM is currently only treated with insulin application, whereas type 2 DM patients have 
more treatment options. Lifestyle modification is recommended and oral anti-hyperglycaemic 
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agents can be administered. Several classes of oral anti-hyperglycaemic agent are known: α-
glucosidase inhibitors of intestinal carbohydrate absorption, biguanides to target hepatic insulin 
resistance, insulin secretagogues to increase insulin secretion, insulin sensitizers or 
thiazolidinediones to target adipocyte and muscle insulin resistance, and intestinal lipase 
inhibitor or orlisat to inhibit fat absorption and promote weight loss in obese patients12. 
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1.2 Pancreas development 
The development of the pancreas has been extensively studied in mice and is a complex process. 
The pancreas arises from the endoderm germ layer, consisting of a two-dimensional sheet of 
cells, which can be found at the edge of the embryo (as shown in Figure 1a). The hindgut and 
foregut are formed by folding the endodermal epithelium anteriorly and posteriorly, respectively. 
In this way, the gut forms a tube by closing it13. Numerous studies have shown that the formation 
and differentiation of the pancreas from gut endoderm requires a series of distinct signals to form 
two independent thickenings called the ventral and the dorsal pancreas. Since, particular regions 
of the gut endoderm are competent to develop into pancreatic cells, additional extrinsic signals 
from adjacent tissues are still needed for the growth and differentiation into pancreatic cells14. 
These regions can be found immediately posterior to the anlagen of the stomach15.  
The dorsal and ventral pancreatic thickenings are not completely identical and develop in an 
asynchronous fashion. This is due to the fact that each part receives a distinct set of signals from 
their immediate surrounding tissues as shown in Figure 2. The dorsal pancreatic bud develops in 
close proximity to the notochord. The presence of the notochord near the dorsal bud is essential 
for its development, particularly in the beginning16-18. Later, the notochord will be displaced by 
the dorsolateral splanchnic mesenchyme, which forms the dorsal aorta located between the 
dorsal epithelium and the notochord. This results in a new set of signals produced by the aorta 
that affect the pancreas. The ventral bud of the pancreas lies near the liver and bile duct 
epithelium that forms on the ventral face of the gut. Organogenesis of the liver and the ventral 
pancreatic bud are closely related. The liver is specified by instructive signals from the cardiac 
mesoderm. In the absence of these instructive signals, the ventral pancreatic program is initiated. 
The ventral pancreatic fate program appears to be a default state, as absence of cardiac induction 
specifies the foregut endoderm in the prospective liver domain to a ventral pancreatic fate15, 19. 
The dorsal pancreatic bud will first arise on the opposite side of the gut tube after which the 
ventral bud arises immediately adjacent to the hepatic diverticulum. As the stomach and the 
intestine rotate, the ventral bud and hepatopancreatic orifice will move along until they fuse with 
the dorsal bud, which is also facilitated by growth of the buds. The ventral bud forms the 
posterior part of the head, or uncinate process, while the dorsal bud forms the remainder of the 
 organ. The ventral duct fuses with the distal part of the dorsal duct to become the main 
pancreatic duct
organogenesis.
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 Figure 1 The development of the pancreas. (a) Front and lateral view of the anterior portion of a mouse 
embryo at 8.25 days of gestation. (b) Fate map of pancreatic domains in the mouse (a
view) but at different 
whereupon the genes hat are specific to those lineages can be first detected to be active in the respective 
progenitor
endoderm (the ventral pancreas) and a medial dorsal domain (the dorsal pancreas). Arrows indicate the 
direction of movement of cells in designated tissues.
 
Most cells composing the ventral and the dorsal bud are apparently uncommitted progenitor 
cells, because they have the capacity to differentiate into any of the mature pancreatic cell types. 
The first differentiated cells that can be
expressing 
pancreatic polypeptide
subsequen
Figure 2 Early stages of pancreatic organogenesis. 
the level of the developing pancreas are shown. The prospective pancreatic portion (green) of the developing 
gut endoderm is specified before the ten
somite stage. Tissues such as the notochord (blue), endothelium (red) and mesenchyme (yellow) support 
pancreatic development. The ten
somite stage roughly corresponds to E10. D, dorsal; V, 
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, gene expression profiling23, 24 and transplantation experiments25, 26 of fetal pancreatic tissue of 
no less than 7 weeks and up to 23 weeks of age to elucidate developmental mechanisms. An 
obvious difference is the gestation period, which is 9 months in human and 3 weeks in mice25. 
Sarkar and colleagues (2008) found that the secondary transition, which is characterized in mice 
by a wave of Ngn3+ cells differentiating into islets and by an increase in β-cells during a short 
period of time, occurs in human throughout the observation period between 9 and 23 weeks of 
gestation24. This has also been confirmed in other studies27, 28. The morphology of the islets 
differs between mouse and man, where β- and α-cells in human islets are scattered around while 
in mouse, β- cells are centrally located and surrounded by the other endocrine cells 21, 22. Rodent 
β-cells have a greater replication capacity compared with human, as described more in detail 
below in paragraph 1.5. We and others hypothesize that the use of human pluripotent stem cells 
may elucidate developmental steps and mechanistic insights in human pancreas. 
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1.3 Histology of the pancreas  
The mammalian pancreas is a compound gland composed of endocrine and exocrine tissues. The 
endocrine tissue consists of five endocrine cell types: β-cells which produce insulin and an 
insulin antagonist called amylin, α-cells, which produce glucagon, δ-cells which produce 
somatostatin, ε-cells which produce ghrelin and γ-cells which produce pancreatic polypeptide 
(PP). These endocrine cells are contained in islets of Langerhans, which comprise 1-2% of the 
cellular mass of the adult pancreas29. Endocrine cells making glucagon, somatostatin, amylin and 
peptide YY are present not only in the pancreas, but also elsewhere in the gut16. The islets of 
Langerhans are scattered throughout the pancreas and form spheroidal clusters embedded in the 
exocrine tissue. They have a highly developed blood supply, whereby up to a few arteries enter 
to the center of the islet, from which they branch into glomerular structures, where collecting 
venules eventually drain into the portal vein30. There is also extensive lymphatic drainage, and a 
rich sympathetic and parasympathetic nerve supply. Smooth muscle is found in the sphincter of 
the pancreatic duct, the sphincter of the bile duct, and the hepatopancreatic sphincter. The 
fibroblastic, lymphatic and smooth muscle components of the pancreas are presumed to arise 
from the abundant mesenchyme enveloping the embryonic buds16. Of the endocrine cells, ~60-
80% are insulin-producing β-cells, 15-20% are glucagon-producing α-cells, 5-10% are 
somatostatin-producing δ-cells and <2% are pancreatic-polypeptide-producing cells. Insulin is 
released from β-cells in response to increased levels of blood-sugar after food intake; this is a 
signal for the target tissues (liver, muscle and fat) to take up glucose. In addition, insulin inhibits 
glucose production in the liver. In contrast, glucagon secretion is stimulated at low blood-sugar 
levels. Glucagon promotes glycogenolysis and gluconeogenesis as the level of glucose in the 
blood decreases. Somatostatin and pancreatic polypeptide exert inhibitory effects on both 
pancreatic endocrine and exocrine secretion8. All islet cell types also express, in addition to their 
specific hormones, a number of gene products characteristic of neuroendocriene cells, such as 
neuron-specific enolase and the homeodomain-LIM protein islet1 (Isl1)16. The exocrine tissue is 
organized into acini, which synthesize digestive enzymes, such as proteases, lipases and 
nucleases, and ducts, which secrete a bicarbonate fluid that flushes the acinar secretions to the 
intestine29. These digestive enzymes are secreted as inactive precursors and become activated 
after they enter the duodenum16. 
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Figure 3. Histology of the pancreas. (a) The pancreas can be found near the duodenum, which is the most 
anterior part of the small intestine. By making a cross-section of the pancreas, two tissue types can be found: 
(b) The exocrine pancreas is organized in acini which take care of the secretion of digestive enzymes and 
ducts which are responsible for flushing the acinar secretions towards the intestine. (c) The endocrine part 
which is composed of islets of Langerhans. These islets consists of five endocrine cell types: β-cells which 
produce insulin and an insulin antagonist called amylin, α-cells, which produce glucagon, δ-cells which 
produce somatostatin, ε-cells which produce ghrelin (not shown) and γ-cells which produce pancreatic 
polypeptide (PP) (taken from Edlund 2002) 
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1.4 Pancreatic transcription factors 
The sequential activation of transcription factor (TF) pathways is essential for the development 
of the pancreas. It seems that some TFs have dual function in both early cellular commitment as 
well as maintaining a mature phenotype. The TF cascade depicted in Figure 4 is a simplified 
schematic overview of the different TFs involved in pancreatic specification, starting with Pdx1. 
Pdx1, a member of the ParaHox group of homeodomain transcription factors, is expressed in 
endoderm and has an important regulatory property in pancreatic development31. During 
organogenesis, Pdx1 is widely expressed in all cells differentiating towards exocrine and 
endocrine components of the pancreas. As the exocrine pancreas appears and the islets begin to 
form into the hormone-producing cells, Pdx1 expression shifts to the endocrine compartment 
primarily to β- and some subpopulations of δ-cells, PP-cells and a few α-cells. Pdx1 (previously 
also named Idx1 and ipf1) is typical example of a TF with multiple functions, as it acquires novel 
functional properties depending on the gestational age of the embryo. Its action evolves from a 
growth and differentiation factor during embryogenesis, to the regulatory TF for several proteins 
of the islets of Langerhans in adults, like Ins, Sst, Glut2 (Glucose transporter 2), islet amyloid 
polypeptide and glucokinase. Pdx1 is also capable of regaining its initial functions when it 
becomes required for the expansion of islet-cell mass during adulthood32.  
Another TF which is expressed very early is Ptf1a. This gene is important for committing foregut 
endoderm towards a pancreatic fate. The Wright group (2002) demonstrated that aside from 
directing pancreatic endoderm cells towards an exocrine fate, it is also a mark for multipotent 
progenitors of the pancreas. Although endocrine cells could still arise upon Ptf1a deletion, a 
small pool of endocrine cells are generated from progenitors which do not express Ptf1a33. 
Seymour and colleagues (2007) suggested that Sox9 marks and maintains undifferentiated 
pluripotent pancreatic progenitors. The expression of Sox9 does not co-localize with the 
expression of Ngn3, which would mean that Sox9 mRNA expression is restricted from endocrine 
committed cells34. 
Ngn3 expression appears to be involved in the development of all endocrine cell types. This 
suggests its importance in the genesis of the islet cell precursor lineage. Pancreatic endocrine 
cells develop from Ngn3+/Pdx1+ precursor cells35. Apelqvist et al. (1999) proved this by creating 
mice wherein the Pdx1 promoter induced expression of Ngn3, which resulted in a massive 
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differentiation of pancreatic progenitor cells into endocrine cells. This acceleration and 
premature differentiation of endocrine cells lead to a shortage of cells that can proliferate, branch 
and differentiate into exocrine cells36. Gu and colleagues (2002) demonstrated unequivocal by 
lineage tracing studies that Ngn3-expressing cells are the islet progenitors of the pancreas37. 
Ngn3 is also important for the expression of NeuroD1, as Ngn3-deficient mice do not express 
NeuroD1. This suggests that NeuroD1 is located downstream of Ngn3. In contrast to Ngn3, 
NeuroD1 is still expressed in mature islets38.  
Cells reaching the Ngn3 state have to make a decision of which endocrine cell type to become. 
One of these faith decisions is regulated by Pax4, a gene part of the Pax (Paired box) gene 
family and expressed in early pancreas. Sosa-Pineda et al. (1997) inactivated the Pax4 gene by 
homologous recombination; this resulted in the absence of mature β- and δ-cells, with a 
considerably higher number of α-cells. Their findings suggests that Pax4 is not required for 
generation of the earliest α and β precursors, but assign the gene an early role in the initial 
processes of endocrine differentiation39. Whereas Pax4 seem to have a key role in β-cell 
development, Collombat and colleagues (2003) were able to show equal importance of the Arx 
gene for α-cells as Pax4 for β-cells. Arx-deficient mice completely lack glucagon-producing 
cells. Interestingly, Pax4 and Arx appear to have opposing actions on the specification of mature 
endocrine cells, which are possible thanks to an inhibitory cross-regulatory network40. 
Nkx2.2 and Nkx6.1, members of the NK homeodomain gene family, also play an important role 
in endocrine specification. Sussel et al. (1998) showed that disruption of the Nkx2.2 gene leads to 
the accumulation of incompletely differentiated β-cells. These cells express some β-cell markers, 
but not insulin, indicating an arrest at a partially differentiated state. They also revealed that 
Nkx2.2 is involved in the differentiation of α- and PP-cells. However, some α- and PP-expressing 
cells remain in the mutant islet clusters, however at reduced numbers, suggesting that there may 
be another regulator that can compensate for the loss of Nkx2.2. The δ-cells are not affected by 
the loss of Nkx2.2 gene expression. It is likely that the formation of δ cells requires other signals 
in addition to the absence of Nkx2.241. The expression of Nkx6.1 during embryogenesis and in 
adults is similar to Nkx2.2 expression with the exception that Nkx6.1 is not expressed in non-β 
islet cells. Sander et al. (2000) examined the role of Nkx6.1 in the hierarchy of transcriptional 
events that lead to β-cell differentiation. Homozygous mutation of the Nkx6.1 gene in mice 
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the β-cell population. The phenotype of mice carrying the homozygous double mutation for 
Nkx2.2 and 
mutation. This study provided the genetic evidence that 
major pathway of 
cell neogenesis in homozygous single 
to a defect in the late
that Ngn3
when two independent regions, dorsal and ventral of the duodenal portion of th
become specified for pancreatic development. Not only is an elevation of 
detected, but also an elevated expression of 
Figure 4 Schematic overview of several transcription factors involved in pancreatic 
of temporal expression
express PDX1
transcription fact
specification.
Nkx6.1 h
β-
 expression does not depend on 
.
 and mature cells 
ors are represented along with the intermediate states to show their importance for cell 
 
as an identical phenotype to mice carrying the 
cell formation. Sander and colleagues (2000) also showed a decrease i
-stage precursors that have progressed beyond the 
 Circular cells
(indicated with rectangles or triangles) 
β-cell formation, thereby preventing the normal expansion of 
Nkx6.1
Nkx6.1
Nkx6.1
 represent intermediate 
 
 mutant embryos, thereby suggesting that this is due 
42
. Normal pancreatic organogenesis is initiated 
15
. 
states
Nkx6.1 lies downstream of 
 between the pancreatic 
during development. Different 
Nkx2.2 homozygous single 
Ngn3 stage. This shows 
specification
Nkx2.2 in the 
e primitive gut 
Pdx1 expression 
 
 on the basis 
progenitor, which 
15 
n β-
 16 
1.5 Replication and neogenesis of β-cells 
Replication and neogenesis of endodermal cells is far better understood in liver compared to 
pancreas. Upon a rather mild injury, hepatocytes re-initiate cell cycle and proliferation of mature 
cells restores the liver mass. However, after a more extensive injury, proliferation of hepatocytes 
is insufficient to replace the liver mass, and facultative hepatic stem cells, located in the 
periductal area, can aid in repopulating specific compartments of the liver mass43, 44. It has long 
been unclear whether a similar repair mechanism exists in the pancreas. However, a number of 
recent studies have suggested that similar mechanisms may be operative in the mouse pancreas. 
Whether this is also true for the human pancreas remains less clear. 
 
a. Replication of pre-existing β-cells 
Dor and colleagues (2004) demonstrated using lineage tracing that pre-existing β−cells have the 
ability to replicate. They generated a rat-insulin-promoter tamoxifen-dependent Cre recombinase 
transgenic mouse. When crossed with a floxed human placental alkaline phosphatase (HPAP) 
mouse, administration of tamoxifen leads to the Cre-mediated removal of a stop sequence which 
allows the expression of the HPAP gene. Therefore, all pre-existing insulin positive cells as well 
as their progeny will be HPAP+. They demonstrated that new islets generated in mice were 
derived from pre-existing β−cells, as no dilution of labelled cells could be detected. This 
however did not exclude the possibility that a small and rare population of stem or progenitor 
cells is present in the adult pancreas that contributes to the β−cell pool. They also performed a 
partial pancreatectomy, and found that the majority of β−cells were HPAP+, suggesting that as in 
the liver, injury to the mouse pancreas results in replication of mature β−cells to reconstitute the 
pool of β−cells45. However, as the injury was relatively modest, these studies could not exclude 
that β−cells would de-differentiate to a stem/progenitor fate and then proliferate and give rise to 
mature β−cell progeny. 
Subsequently the same group demonstrated that replication of β−cells and not de-differentiation 
to a more immature progenitor can support regeneration of β−cells in murine pancreata46. For 
these studies they used mice wherein the diphteria toxin receptor is introduced under the 
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regulation of the insulin promoter. In these mice β−cells can be ablated by administration of 
doxycycline, which causes activation of the diphtheria toxin receptor in β−cells specifically, and 
hence provides control over the onset and the termination of β−cell kill. When four-week-old 
mice were treated with doxycycline for 1 week, 70-80% of β−cells died, and mice became 
hyperglycaemic. However, after 8 months mice became normoglycemic. To define whether this 
was due to replication of β−cells, they used the tamoxifen-Cre model described by Dor et al. 
2004, in combination with BrdU labelling45. They found that the majority of HPAP+ cells were 
BrdU+ and the majority of BrdU+ cells were HPAP+. This demonstrated that the majority of new 
β−cells are derived from HPAP+ cells that proliferated during the period of BrdU administration, 
and that few if any other cells contribute to the regenerated β−cell pool. There is also evidence 
that under steady state conditions β−cells replicate slowly, which increases during pregnancy, 
following 50% partial pancreatectomy or by adding Exendin-4, a glucagon-like-peptide (GLP)-1 
agonist47. 
The frequency of β−cell replication in humans is difficult to investigate, as lineage tracing is not 
possible. Different approaches have been used to address this question. Gershengorn and 
colleagues (2004) demonstrated that human islet-derived precursor cells dedifferentiate into 
fibroblast-like cells, and can be redifferentiated into hormone-expressing islet-like cells through 
a reversible epithelial-to-mesenchymal transition (EMT)48. This is in line with the “self-
duplicating β-cell”-theory advanced by Dor et al. (2004), which now is shown to make use of the 
EMT. The second approach used abdominal computer tomographies in 135 children between 4 
weeks and 20 years. Morphometric analyses of the tail of the pancreas showed that the β−cell 
mass expand from birth to adulthood by an increase in islet size rather than increase in the 
number of islets49. Staining pancreata with an anti-Ki67 antibody demonstrated that replicating 
β−cells peak during infancy. Reers et al. (2009) also showed that replication (one positive cell in 
five islets) is a rare event that this is age-dependent, and that reduced PDX1 expression was 
associated with impaired islet turnover in older subjects50. Butler and colleagues (2010) looked at 
islets of pregnant women and found that an increase in β-cell number was due to the emergence 
of newly formed small islets rather than to an increase in β-cell number of pre-existing islets51. 
The latter observation is not in concordance with studies performed in mice52, and points out to a 
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difference in adaptation between human and rodents. Therefore, more investigation in human 
subjects will be needed to confirm previous results. 
b. Neogenesis of β-cells 
Although the studies above demonstrate that β−cell proliferation occurs in pancreata, they do not 
exclude that as in the liver, following extensive damage; (facultative) progenitors are responsible 
for β−cell neogenesis. As progenitors for endocrine cells in the pancreas express the transcription 
factor Ngn3, a number of investigators have assessed whether Ngn3+ cells can be found in adult 
pancreas. Forced ectopic expression of Ngn3 leads to a massive differentiation of pancreatic 
progenitor cells into endocrine cells. Moreover, Ngn3-/- mice do not develop endocrine hormone 
producing cells, and die, consequently, at birth 36. Upon maturation of islet cells, Ngn3 is no 
longer expressed38. 
Although Ngn3+ cells could not be detected in pancreata following a 50% partial 
pancreatectomy53, Ngn3+ cells could be selected from adult pancreata after ductal ligation54. 
Using a lineage tracing technique that permanently labels glucagon- and insulin-positive cells, 
Xu et al. (2008) could rule out the possibility that islet cells de-differentiated to generate Ngn3+ 
progenitor cells that then re-differentiate to hormone positive cells. The Ngn3+ cells could be 
found lining the duct of the adult mouse pancreas, and may reflect the pancreas equivalent of the 
hepatic progenitors that are also found in the periductal region43. Collombat et al. (2009) 
demonstrated that overexpressing Pax4 in glucagon-expressing cells, leads to refating to β−cells, 
but this occurred via an Ngn3+ intermediate state, suggesting de- and re-differentiation55. The 
previous studies strongly suggest the existence of a pancreatic endocrine progenitor cells in adult 
tissue in mice. It is not clear where these cells originate from. Some reports have suggested that 
in human pancreatic the ductal compartment tissue is the source of newly generated β-cells56, 57. 
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1.6 Alternative cell sources for β-cell therapy 
a. Reprogramming towards β-cells 
The reprogramming of different cell types towards β-cells has been successful in mice. Therefore 
most of the reports mentioned in this section are from rodent studies. Whether, the findings also 
hold true for human cells remains to be determined, as there is evidence for species specific 
differences in ontogeny and regeneration of endocrine pancreas. 
 
Liver cells 
Refating endodermal cells to β−cells can be achieved by transgenic overexpression of 
pancreas/endocrine-specific TFs. One of the first reports demonstrated that in vivo introduction 
of the Pdx1 transgene into hepatocytes can activate β−cell features58. Using a first-generation 
andenoviral vector Pdx1 was ectopically expressed in the liver of 14-week old BALB/c and 
C57BL/6 mice. This induced expression of Ins-2, but not Ins-1. When Pdx1 as well as a rat Ins-1 
promoter (RIP) followed by the human INS cDNA, were co-expressed, human INS could be 
detected. This suggested that the promoter of Ins1 in mouse hepatocytes might be methylated or 
silenced in another manner. Immunoreactive INS could also be found in extracts derived from 
hepatic tissue, even if only at 1% of immunoreactive insulin in pancreas extracts. To assess if 
hepatic insulin production could reverse hyperglycemia, mice were first made diabetic and then 
treated with the Pdx1 encoding adenovector. Although glycemia levels decreased on day 2, it is 
unclear whether this was due to insulin or by glucokinase, which was also induced following 
overexpression of Pdx1. In addition, which cells were transduced and partially refated in the liver 
was unclear. In vitro data showed that primary cultures of hepatocytes could not be 
transdifferentiated, suggesting that perhaps a progenitor population in the hepatocytes was 
targeted in vivo.  
As the first generation adenoviral vectors are hepatotoxic, Kojima et al. (2000) used helper-
dependent adeno (HDAD)-viral vectors, which do not have the same toxic effects as adenoviral 
vectors to trans-differentiate hepatocytes to β−cells59. They over-expressed Pdx1 using HDAD-
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viral vectors in diabetic mice. An effect on glycemia was seen for only one week. The authors 
speculated that is due to the fact that Pdx1 also induced the expression of several pancreatic 
exocrine enzymes that lead to the destruction of the newly generated β-cells. Increasing the dose 
of viral vector did not prolong the effect on blood glucose levels, but caused toxicity instead, and 
animals died 4 weeks after infusion of the Pdx1 containing HDAD-viral vectors, but not with 
empty vector. As the mice in the study by Ferber et al. 2000 were not analyzed for more than 8 
days, this hepatoxic effect of Pdx1 due to the use of the first-generation adenovector was not 
seen in their study58. 
In a subsequent study the effect of overexpression of NeuroD1 alone or combined with 
betacellulin in the liver of diabetic mice was tested. This resulted in normalization of blood 
glucose levels within 3 weeks, which was maintained for up to 120 days. Several β−cell specific 
transcripts, including Ins-1, Ins-2, Pcsk1, Psck2, Kcnj11 and Abcc8 could be detected in the 
transduced liver. Also, the pancreas-specific glucokinase mRNA was detectable. In addition, TFs 
downstream from NeuroD1 as well as endogenous NeuroD1 transcripts could be detected. The 
liver contained structures with the morphology of islets with 30-50 insulin-positive cells. The 
islets contained also cells with ultrastructural features of β−cells, i.e. secretory granules. The 
number of newly formed islets was comparable to the number of islets transplanted in humans60.  
Another study tested the effect of forced expression of Ngn3 in hepatocytes. They transduced the 
liver with a HDAD viral vector encoding for the Ngn3 and betacellulin (Btc) gene. Using lineage 
tracing, they demonstrated that initially cells could be identified that co-express Alb and Ins 
which was followed in a second phase by transduction of periportal oval cells61, which were 
responsible for β-cell neogenesis. This resulted in the reversal of DM, as well as in normalization 
of glucose secretion and reversed ketonemia. Further, the transcriptome of the neo-islets 
generated in the liver was highly similar to that of primary pancreas derived islets. The authors 
used the term trans-determination instead of trans-differentiation to indicate that the fate switch 
was caused by altered fating of endoderm progenitors, and not from mature hepatic cells60. 
Similar studies have been performed using human hepatic cells in vitro. Zalzman and colleagues 
(2005) immortalized human liver derived epithelial cells, which are capable of generating biliary 
cells and hepatocytes. They subsequently transduced this cell line with the rat Pdx1 gene, and 
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demonstrated that the transduced cells could secrete INS upon glucose stimulation, and 
expressed transcripts for NGN3, NEUROD1 and NKX6.1. However, the cells continued to 
express hepatocyte specific gens such as DPPIV and γ-glutamyl transpeptidase, and stained 
positive for GLYCOGEN. Nevertheless, the cells could restore euglycemia in diabetic mice 2 
weeks after transplantation62. An improved protocol was published by the same group, which 
increased the expression of several genes important in the development of β−cells including 
NEUROD1, NKX2.2, GCK and PC 1/3 and established more quickly stable euglycemia62. As 
transduction of Pdx1 in murine or rat hepatocytes can refate them to β-cells58, this also appears 
to be possible in immortalized human hepatic progenitor cells62, 63. 
In another approach, human adult and fetal hepatocytes were transduced with a bi-functional 
adenoviral construct containing a rat insulin promoter-driven green fluorescent protein (GFP) 
and a PDX1 gene under the control of a cytomegalovirus (CMV) promoter. In ± 10-25% of the 
adult human hepatocytes the insulin promoter became activated, which was not significantly 
different from what was seen in fetal hepatocytes. The transdifferentiated adult cells produced 
insulin following glucose administration, and restored normoglycemia in vivo. This led to the 
conclusion that the fetal or adult origin of the hepatocytes does not have a substantial effect on 
trans-differentiation64. 
 
Pancreatic endocrine cells 
Zhou et al. 2008 evaluated several TFs that may redirect the phenotype of exocrine pancreas 
cells to insulin producing β-cells. They identified 9 TFs that when mutated cause developmental 
β-cell defects. As adenoviral vectors transduce endocrine cells very poorly, they were sure to 
transduce mainly exocrine cells. The transduction of 9 factors together with nuclear GFP 
encoded by adenoviral vectors caused the appearance of GFP positive transduced cells that co-
express insulin65. They narrowed down the mix of TFs to Ngn3, Pdx1 and MafA as being 
necessary to reprogram exocrine cells to insulin-positive cells. The insulin-positive cells did no 
longer express exocrine marker genes (such as amylase or Ptf1a), mesenchymal markers (such as 
nestin and vimentin) or the neuronal marker Tuji. They also did not express any of the other 
pancreatic endocrine hormones. To definitively prove that an exocrine pancreatic cell was trans-
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differentiated, a genetically modified mouse line (Cpa1CreERT2) was crossed with the R26R 
reporter line, to label mature exocrine cells with β-galactosidase in vivo66. Most of the β-
galactosidase+ cells became insulin+ after transduction with Ngn3, Pdx1 and MafA. The trans-
differentiated cells could revert hyperglycemia in vivo. To exclude de-differentiation, which is 
characterized by a rapid division and expression of Sox9 and Hnf6, they looked at BrdU 
incorporation of the refated cells. Only 3.2% were BrdU+, whereas no Sox9 and Hnf6 expression 
could be detected. This led them to conclude that the newly formed β-cells were likely to be 
generated through trans-differentiation and not through de-differentiation and subsequent re-
differentiation of exocrine pancreatic cells. 
 
b. Differentiation of other adult non-β-cell sources 
Bone marrow cells 
There has also been interest in testing whether stem cells from bone marrow (BM) might be able 
to generate hormone producing pancreatic cells. One study demonstrated that BM cells might be 
capable of generating β−cells67. Following intravenous infusion of INS-GFP male donor BM 
cells, these cells could be found back in the pancreas of the female recipients. The group also 
used BM cells from INS-CRE male mice in female ROSA-stop-loxP-eGFP mice, to exclude 
fusion events, since no GFP-expressing cells could be identified. They suggested that BM cells 
could trans-differentiate into hormone producing β−cells. However, others68 have been unable to 
reproduce the studies by Ianus et al. (2003) using the same model and including others like 
partial pancreatectomy and streptozotocin-induced destruction of β−cells.  
A few studies tried to determine whether human BM cells would be able to trans-differentiate 
into β−cells. Butler and colleagues (2007) examined 31 human pancreata obtained from patients 
who underwent hematopoietic stem cell transplantation from a donor of the opposite sex. Using 
in situ hybridization they examined the presence of the Y chromosome in β-cells, but were 
unable to identify male cells that were pancreatic β−cells in nondiabetic humans69. 
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Mesenchymal stem cells 
Mesenchymal stem/stromal cells (MSC) were first described in the 1970s by Friedenstein et al. 
(1974) as fibroblast colony forming cells70. In the 1990s, the cells were renamed mesenchymal 
stem/stromal cells by Caplan and others71-73 . MSCs are multipotent progenitor cells that can give 
rise to osteoblasts, chondrocytes, adipocytes and smooth muscle cells. MSCs can be harvested 
from among other tissues, BM, adipose tissue, fetal lung, Wharton’s jelly, amniotic fluid72, 73. It 
is unclear whether MSCs can generate β−cells. Lee and colleagues (2006) injected human MSCs 
intra-cardially and found an amelioration of glucose levels in diabetic mice, although no 
circulating human insulin levels were detected. In the mouse pancreata, they found an increased 
immunoreactivity for mouse insulin and an increase in islet number compared to untreated 
diabetic mice, suggesting that human MSCs can increase insulin secretion of mouse β-cells74. 
Sordi et al. (2008) isolated MCSs from pancreas and infused them into diabetic mice. An 
improvement in the control of glycemia was observed due to the improved vascularization 
induced by the MSCs75. Some studies do suggested that MSCs can generate β-cells when 
injected systemically into the tail vein of diabetic mice76. Therefore it is still controversial 
whether MSCs have the capacity to give rise to lineages other than mesoderm.  
Human pluripotent stem cells (hPSCs) 
Embryonic stem cells (ESCs) are pluripotent as they have the ability to differentiate in all cell 
types of the mouse or human, including germ cells, and have indefinite self-renewing ability. 
Although murine ESCs were first isolated in 1980, it was only in 1998 that human ESCs were 
isolated from embryos generated from in vitro fertilization77. Human ESCs express cell surface 
markers like TRA-1-60, TRA-1-81, stage-specific embryonic antigen (SSEA)-3, SSEA4 and 
alkaline phosphatase. The use of human ESCs is however ethically encumbered, as it requires the 
use of human embryos. In 2006 and in 2007, the team of S Yamanaka identified a method to de-
differentiate any adult cells from mouse or human, or other species to induced pluripotent stem 
cells (iPSCs) by overexpression of OCT4, SOX2, KLF4 and cMYC78. iPSCs can be derived using 
integrating vectors such as lentiviral and retroviral vectors; transposons; non-integrating vectors 
such as adenoviral vectors and Sendai virus; introduction of the TF proteins, modified mRNAs; 
as well as microRNAs79. One main question remains: “How identical are iPSCs compared with 
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ESCs?”. For a more detailed overview concerning this topic, see the review from Robinton and 
Daley79. Mayshar et al. (2010) showed that the amplification of chromosome 12 is present in 
both cell types80. This was confirmed by Taapken and colleagues (2011) who also showed that 
the observed genetic aberrations are independent from cell type, passage number, cell support 
and reprogramming procedure using a large-scale study of several hundred cell lines81. Although 
there is no difference in the incidence of genetic abnormalities, some reports find different 
chromosomal alterations in hESCs vs. hiPSCs. A gain of chromosome 1q (1q25-1q41) or 
trisomy of chromosome 17 are commonly seen in hESCs but not in hiPSCs80, 81. There is also an 
instability effect observed in the epigenome of hPSCs specifically where it concerns the 
methylation pattern of a subset of imprinted genes as well as X-chromosome inactivation82. 
Guenther and colleagues (2010) looked at histone modifications patterns in hPSCs and observed 
no differences in the pattern of  H3K27me3 and H3K4me3 marks between hESCs and hiPSCs83. 
Also a study performed with mouse pluripotent stem cells reported negligible immunogenicity 
for both cell types84, which is important for cell-based therapy. Overall, most studies conclude 
that hESC and hiPSCs are generally comparable cell lines. Specific attention should be given 
regards to the cell source from which iPSC are generated, because several studies showed 
varying reprogramming susceptibility amongst different cell types85-87. Daley’s group (2010) 
analyzed the influence of cell type origin and came to the same conclusion as Hochedlinger’s 
group (2010) that this phenomenon can be attributed to the epigenetic memory of the donor 
tissue, which has to be fully erased to establish the ground state of pluripotency. If not, residual 
epigenetic marks may influence the differentiation potential of iPSC-progeny88, 89, although Pole 
et al. (2010) demonstrated that long-term passage of iPSCs from different cell sources erases 
many of the epigenetic differences present during early passage89. Another example is that upon 
reprogramming of β-cells, the iPSC still retain an open chromatin structure as well as a unique 
methylation signature compared to other hPSCs. The β-cell derived iPSCs used in this study had 
a greater tendency to differentiate towards insulin-expressing cells compared to non-β-cell 
iPSCs90. 
To induce pancreatic cells from hPSCs, it is important to recapitulate in vivo development 
starting from the blastocyst stage, through the primitive streak, passing through definitive 
endoderm, gut tube endoderm (GT), anterior foregut (AF), pancreatic endoderm and finally 
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towards endocrine hormone-producing cells. It is generally acknowledged that the use of 
Activin-A induces definitive endoderm in ESCs91 and can be improved with Wnt3A92. Sonic 
Hedgehog (Shh) which is known to repress pancreatic endocrine differentiation93 must be 
inhibited, to allow the further development into GT and AF. Retinoic acid (RA) and NOGGIN, 
which blocks bone morphogenetic protein (BMP) signaling, are crucial to generate pancreatic 
endoderm94. D’Amour et al. (2006) have demonstrated that it is possible to generate pancreatic 
hormone-expressing endocrine cells from hESCs, using signals described above that regulate 
pancreas development in vivo. hESC progeny expressed pancreatic hormones like insulin, 
glucagon, somatostatin, pancreatic polypeptide and ghrelin, but the differentiated cells were only 
minimal glucose-responsive92. In addition, many of the in vitro generated progeny consisted of 
poly-hormonal cells. They subsequently adapted the protocol and grafted hESC derived 
endocrine progenitors, expressing mainly PDX1 and NKX6.1, in vivo to allow further maturation. 
Glucose-responsive cells were formed in vivo 30 days after grafting the ESC progeny in 
euglycemic mice. To demonstrate that the graft was capable of producing insulin, they 
eliminated the β−cells of the mice after transplantation using streptozotocin, which does not 
affect human β−cells and demonstrated persistent euglycemia for several months95. However, 
this was only possible with one hESC line, and other groups, using similar endodermal 
committed cells could only partially reproduce these findings, showing only limited endocrine 
cell development after a much longer time period than described before96.  
Reports that hiPSC can be induced to differentiate to endocrine pancreatic cells have not yet 
been published. Alipio and colleagues (2010) succeeded in reversing the hyperglycemia of 
diabetic mouse models using murine iPSC-derived pancreatic β−like cells. They made use of two 
different mouse models which represent both type 1 and type 2 DM to demonstrate that iPSC 
derived progeny is able to reduce insulin resistance and reverse glucose toxicity97. 
Thus, although it appears possible to induce differentiation of ESC towards definitive endoderm, 
and also towards pancreatic endoderm, full maturation to terminally differentiated β−cells 
remains difficult to achieve. Some groups have therefore started high-throughput compound 
screens to identify novel molecules that might aid in the different commitment steps. Using this 
approach, the Melton group identified molecules that either improve commitment to definitive 
endoderm (IDE1 and IDE2), or commitment to pancreatic endoderm (indolactam V (ILV)98, 99. 
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1.7 Genome editing of PSCs 
The extensive differentiation and regenerative potential of PSCs makes them a very interesting 
tool for studying human developmental, and perhaps even for therapeutic approaches. Although 
progress is being made in differentiating PSCs to mature cell types, in general PSC progeny 
remains impure and mixed populations after sequential differentiation of the PSCs towards cell 
types of multiple organs like liver, pancreas, intestine and lung. Therefore, the prospective 
isolation of specific intermediary and mature cell types would be helpful in dissecting the 
cultures, as well as to bypass the issue of transplanting undifferentiated PSCs that can give rise to 
teratomas77, 103. One method for selecting specific cell types is based on antibodies against 
specific cell-surface markers for each cell type of interest. Unfortunately, a specific cell surface 
antigen is not available for many intermediary progenitors and mature cells in for instance the 
pancreas.  
Therefore creation of transgenic reporter cell lines would aid enormously to elucidate the 
molecular signature of hPSCs-derived progenitors and mature cells100, 104. The ability to 
genetically manipulate mouse ESCs has revolutionized the biomedical and biological sciences. 
Applying this technology to human PSCs, i.e. generation of transgenic or knock-in reporter cell 
lines that target specific steps during PSC differentiation, would be interesting for many 
biological studies and transplantation approaches105-107. This genome editing in PSCs can be 
achieved by many ways including amongst others, homologous recombination (HR) using viral 
vectors, bacterial artificial chromosome, zinc finger nucleases (ZFNs), transcription activator-
like effector nuclease (TALENs)107-109. A more recent genome editing technique has been 
developed which is termed: clustered regularly interspaced short palindromic repeats 
(CRISPR)/CRISPR-associated (CAS) system. Upon complementarity between an RNA and 
DNA sequence, the Cas9 protein will be directed towards the site to allow cleavage of the 
DNA110. The CRIPSER/CAS9 system is more efficient than TALENs, even if it is not yet clear 
how many off target cuts will occur111. An overview of the efficiency of the different genome 
editing techniques was taken from Cheng et al. 2012 and is shown in Table 2. Previous reports 
using genetically modified hPSCs already showed the power of this application for the 
prospective isolation of certain cell types for developmental studies. For example, Wang and 
colleagues (2011) were successful in isolating SOX17-expressing cells from differentiating 
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hESCs. They showed that these cells could further develop into liver, pancreas and intestinal 
epithelium, rendering it an interesting tool to analyze developing endoderm. In addition, they 
could indentify surface markers for the SOX17-expressing endoderm progenitor100. Another 
group also made use of a knock-in, this time for the NKX2.5 gene. When directing this reporter 
cell line towards a cardiac fate, they could identify NKX2.5-expressing cells as human cardiac 
progenitors and cardiomyocytes. By doing so, they also identified specific surface markers for 
these cells112. Other groups reported the use of a knock-in for the INS gene in hPSCs. 
Unfortunately, the cells were not glucose responsive in vitro113, 114 and upon transplantation in 
mice, they only differentiated into GCG-expressing cells in vivo114. The outcome of these studies 
was rather unexpected, but does reflect the importance of the choice of the targeted gene for 
lineage tracing purposes. It should be noted that the INS positive cells selected in the study by 
Basford et al. (2012), mostly express INS in combination with other hormones, suggesting that 
the INS-expressing population still contained immature endocrine cells. The authors hypothesize 
that the maturation into GCG-expressing cells could be due to lack of a factor(s) required for the 
conversion of pancreatic endodermal cells into β-cells. A more recently published study from the 
Sander’s group (2013) has shed more light on this observation. They demonstrated that terminal 
differentiation into endocrine cells is not possible in vitro, due to aberrant histone modification 
marks. They prove this by comparing the epigenetic profile of in vivo matured with in vitro 
matured endocrine cells115. 
 
Table 2 Overview of different genome editing techniques (taken from Cheng et al. 2012). *CRISPRs was not 
included in the overview, therefore direct comparison is difficult. 
 Viral vectors BAC ZFN TALEN *CRISPRs 
Efficiency 1-78% 10% 0.3-48% 11.8-75% Higher than 
TALEN 
Accuracy Random Specific Specific Specific Specific 
Positional 
effect 
High Low Low Low Low 
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One main hurdle for the targeting of hPSCs is that it is significantly more difficult to clonally 
select hPSCs, because they undergo apoptosis much more quickly upon dissociation into single 
cells compared with mPSCs, and hence need to be passaged preferably as cell clumps. This 
problem can be largely overcome by the use of neurotrophins or ROCK inhibitor Y-27632 that 
greatly increases the cloning efficiency of hESC without affecting their pluripotency and 
genomic instability. Pyle et al. (2006) made use of the receptors of the tropomyosin-related 
kinase (TRK) to inhibit hPSC apoptosis. They identified three TRK ligands, neurotrophin 3, 
neurotrophin 4 and brain-derived neurotrophic factor, which support the survival of single hESC 
through the phophatidylinositol-3-kinase pathway. Without adding these factors the survival rate 
of dissociated hESC was lower than 1%116, 117. Another group in Japan demonstrated that the 
selective Rho-associated kinase (ROCK) inhibitor, Y-27632, also diminished dissociation-
induced apoptosis and increased the efficiency of clonal hESC growth118. 
We choose to generate NGN3eGFP-hESC lines from H1 and H9 using the ZFN technology 
combined with the use of Y-27632 to allow for single-cell survival. These genetically modified 
lines are different from most previously reported transgenic lines, because we make use of a 
knock-in add-on strategy. This approach retains two intact NGN3 alleles, whereas most studies 
have created lineage-tracing lines by disrupting one allele of the targeted gene. This ZFN 
technology is based on the use of a nuclease, FokI, which is linked to three or four zinc fingers. 
Each zinc finger is able to recognize a specific nucleotide triplet. When two ZFN pairs are in 
close proximity of each other, a double strand break (dsb) can be induced in the DNA through 
the FokI domain. In this way, the genome will need to repair the dsb through homologous end-
joining or through HR using exogenous homologous DNA, which can be used to introduce 
transgenic expression cassettes108. Besides the very efficient targeting of hPSCs using ZFNs, 
there are also some disadvantages related to this technology, like the off-target effect and the 
genotoxicity, as well as the high cost to design a proper ZFN pair. Therefore, much effort has 
been put in the use of TALEN instead, which would not suffer of previous disadvantages109. 
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2 AIMS 
 
Human embryonic stem cells (hESCs) are being evaluated as a possible source of β-cells to treat 
DM type 1. Investigators world-wide have used growth factors and/or small molecules to mimic 
pancreatic development in vitro to generate insulin-producing β-cells from hESCs92, 95, 98, 99, 119. 
Some groups documented that hESC-derived β-cells, like primary islets, can reverse 
hyperglycemia in mice immediately following grafting of the hESC progeny120, 121. Other groups 
have grafted mixed ESC progeny consisting chiefly of PDX1- and NKX6.1-expressing cells to 
reverse hyperglycemia in diabetic mice. However, development of normoglycemia required 
further in vivo maturation of the hESC-derived pancreatic endoderm95, 119. Kelly et al. (2011) 
selected pancreatic endoderm progenitors with an anti-CD142 antibody, or endocrine cells with 
an anti-CD200 and -CD318 antibody. CD142 selected cells yielded islet-like clusters, ductal and 
exocrine tissue after implantation, whereas CD200- and CD318-enriched population gave rise 
mainly to glucagon (GCG)-positive cells101. All these studies relied on the transplantation of 
mixed or not completely pure cell populations, which in some cases lead to the generation of 
teratomas95, 119. Therefore, it remains unclear which cell is responsible for the generation of 
human insulin-producing β-cells.  
We hypothesized that the isolation and characterization of a specific pancreatic endocrine 
progenitor population would provide a useful tool for the characterization of mechanisms that 
underlie generation of β-cells from hESCs in vitro and/or in vivo, and could serve eventually as a 
valuable and safe source for cell therapy. In mouse, Ngn3-expressing cells are known to give rise 
to all hormone-secreting endocrine cell types in the pancreas36. Upon maturation of islet cells, 
Ngn3 is no longer expressed38. Therefore NGN3 might be a useful marker for the identification 
of human pancreatic endocrine progenitors. We here explored this possibility by selecting 
NGN3-expressing cells from differentiating hESCs in vitro. Zinc finger nuclease (ZFN)-
mediated homologous recombination (HR) was used to target a reporter-selectable cassette at the 
C-terminus of NGN3, allowing the isolation, purification and characterization of NGN3-
expressing cells.  
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2.1 Aim 1: Genetically modify hESCs to generate a reporter cell line for NGN3 
To address whether NGN3 plays a role in human cells as shown before in mice by Gu et al. 
200237, we decided to genetically modify hESCs with the ZFN technology to generate a lineage 
tracing tool for NGN3. In doing so, we also checked whether the cells were affected by the 
targeting experiment through differentiations, teratoma formation assays, the detection of 
pluripotency markers and array-comparative genomic hybridization (array-CGH). 
2.2 Aim 2: Characterization of the prospectively isolated NGN3eGFP+ cells 
Upon differentiation of the NGN3eGFP-hESC lines, we directed the cells towards a pancreatic 
endoderm fate to induce NGN3+ cells. These cells were enriched using antibiotic selection and 
sorted out by fluorescence-activated cell sorting (FACS). Further characterization of these cells 
was performed by quantitative-real time polymerase chain reaction (qRT-PCR) and 
immunostaining. 
2.3 Aim 3: Assessing the potential of the NGN3eGFP+ cells 
The potential of these NGN3eGFP+ cells was assessed in an in vitro differentiation experiment as 
well as in an in vivo transplantation assay. In this way, we could see if these cells have the 
potential to generate human pancreatic endocrine cells. 
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4 MATERIALS AND METHODS 
 
4.1 Cell culture 
The human ESC lines, H9 and H1 were purchased from Wicell Research Institute (Madison, 
WI). Experiments were performed at the Katholieke Universiteit Leuven with approval from the 
Medical Ethics Committee, UZ Leuven, Gasthuisberg. The ESCs were cultured on inactivated 
mouse embryonic fibroblasts (iMEFs) (250,000 cells/well, Globalstem, GSC-6301G) in 
DMEM/F12 (Life Technologies, 31330095) supplemented with knockout serum replacement 
(Life Technologies, 10828010), penicillin and streptomycin (Life Technologies, 15140122), 
glutamine (Life Technologies, 25030024), nonessential amino acids (Life Technologies, 
11140035), basic fibroblast growth factor (bFGF, 4ng/ml, Life Technologies, PHG0023) and β-
mecaptoethanol (Sigma, M6250). Passaging at 1:3-4 was done using collagenase IV (1mg/ml, 
Life Technologies, 17104019) for cells maintained on iMEFs. For differentiation purposes, cells 
were harvested through enzymatic dissociation and plated on 2% matrigel (Becton Dickinson, 
354230) coated wells in mTESR medium (Stem Cell Technologies, 05870). After the cells 
reached 60-70% confluency, differentiation was initiated as depicted in Figure 7a. Pancreatic 
differentiation medium consists of 55% DMEM with 1000 mg/L D-Glucose (Life Tecnologies, 
31885-023), 2% fetal bovine serum (Hyclone, CH30160.03), 0,1% (0.1 mM) β-mercaptoethanol 
(Gibco, 31350-010), 0.1% Penicillin-Streptomycin liquid (Life Technologies, 15140122), 40% 
MCDB 201 medium with trace elements, L-glutamine and 30 mM HEPES (Sigma, M6770), 
ITS+1 (100×) (Sigma, I2521) , 0.1 mM L-Ascorbic acid (Sigma, A8960). Wnt3a (50ng/ml 
prepared in PBS containing 0.1% bovine serum albumin (BSA) (Sigma, A-8806), R&D, 5036-
WN) and Activin A (100ng/ml prepared in PBS containing 0.1% bovine serum albumin (BSA) 
(Sigma, A-8806), R&D, 338-AC) are used for stage 1. NOGGIN (100ng/ml prepared in PBS 
containing 0.1% bovine serum albumin (BSA) (Sigma, A-8806), R&D, 6057-NG), anti-SHH 
(2.5ug/ml prepared in PBS containing 0.1% bovine serum albumin (BSA) (Sigma, A-8806), 
R&D, MAB4641), nicotinamide (NA) (10mM prepared in MilliQ water, Sigma, N0636) and 
retinoic acid (RA) (10µM prepared in ethanol (Sigma, E7023), Sigma, R2625) were added 
between d4 until d16 (stage 2). 
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The NGN3eGFP+ enriched cells were cultured as clusters: 10,000 cells/well were plated in 96-
well low-attachment plates, Hydrocell 96U Microwell (Thermoscientific, Nunc, 174908) with 
NOGGIN, anti-SHH, RA and NA as described before. To allow cluster formation, plates were 
spun at 200g for 5min. After two days, medium was replaced with RPMI1640 medium (Life 
Technologies, 11835105) with 0.05w% BSA (Sigma, A-8806), 0.1% Penicillin-Streptomycin 
liquid (Life Technologies, 15140122) containing NA (10mM prepared in MilliQ water, Sigma, 
N0636) and insulin-like growth factor I (IGFII) (50ng/ml prepared in PBS containing 0.1% 
bovine serum albumin (BSA) (Sigma, A-8806), R&D Systems, 292-G2) for an additional 24 
days  
 
4.2 RNA isolation and quantitative real time-polymerase chain reaction (qRT-PCR) 
Total RNA was extracted using the RNAeasy mini kit (Qiagen, 74104) and cDNA was 
synthesized from 1µg total RNA using Superscript III reverse transcriptase (Life Technologies, 
18080-51) both according to manufacturer’s protocol. For qPCR: the cDNA underwent 40 
rounds of amplification on a Mastercycler® ep Realplex qPCR instrument (Eppendorf) as 
follows: 40 cycles of a 2-step PCR (95°C for 15 sec, 60°C for 45 sec) after initial denaturation 
(50°C for 2min, 95°C for 2 min) using specific primers, Platinum SyBRGreen qPCR supermix-
UDG (Life Technologies, 11733-046). and 2µl cDNA. For normalization purposes, PPIA was 
used as a housekeeping control and results are shown in deltaCt = Ct (gene of interest) - Ct 
(PPIA). Primers used were synthesized at IDT Technologies. A list of the primers can be found 
in Table 3.  
 
4.3 NGN3 gene targeting 
The ZFNs were designed in collaboration with Sigma. The ZFN binding site is shown in Figure 
6a. The validation of the ZFNs was performed by Sigma. Human K562 cells were used to verify 
the specificity of the ZFNs. The NGN3 ZFNs were able to target 8.7% of the cells (see Figure 
6a). Also, the Cel-1 assay performed on the NGN3 gene demonstrated sucessful targeting of the 
NGN3 allele (see Figure 6c). The different components for the donor construct for NGN3 were 
cloned in the pCR2.1 plasmid. For the homology arms of NGN3 we used up to 800bp amplicons 
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surrounding the stop codon, amplified from the genomic DNA of hESCs, see Appendix for more 
details. 
 
Figure 6. (a) ZFN binding site, in red the cut site is shown. (b) The NGN3 ZFN mRNA is shown to be active in 
human K562 cells. (c) Cel-1 assay resolved on 10% TBE-PAGE 
 
HESCs cells were dissociated with 0.05% trypsin. For the nucleofection of ZFN mRNA and 
donor plasmid into hESCs, 2-3 million hESCs per condition were washed twice with PBS (Life 
Technologies, 20012-019). The nucleofection was performed with the Amaxa nucleofector 
(Lonza) using nucleofection solution 2 of the hESCs nucleofection kit and with program A34. 
The nucleofected cells were plated on inactivated DR4 MEFs (Globalstem, Z8030001) 
containing 10 mM ROCK inhibitor Y-27632 (Sigma, Y0503) and selected with hygromycin 
(H9:50ug/ml and H1:25ug/ml prepared in MilliQ water, Sigma, H3274) for one to two weeks. 
Surviving colonies were individually picked and expanded. 
 
4.4 PCR genotyping 
DNA was extracted from cell pellets using the QiaAmp DNA mini kit (Qiagen, 51306) and 
100ng was used to perform the PCR reactions. Junction assay primers (see  
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a in red) for the targeted integration of our reporter construct with an annealing temperature of 
60°C with the Expand High Fidelity PCR system (Roche, 11 732 650 001). Random integration 
primers (see Figure 7a in blue) were used for detecting random integration of the plasmid with an 
annealing temperature of 60°C as well, but with the Platinum Taq DNA polymerase High 
Fidelity (Life Technologies, 11304011). 
 
4.5 Teratoma formation and analysis 
Three to four wells of HESCs were collected with collagenase IV and were resuspended in 120µl 
PBS (Life Technologies, 20012-019) and injected with 120µl matrigel (Becton Dickinson, 
354230) subcutaneously in the back of severe combined immunodeficient (RAG2γc) mice. 
Tumors generally developed within 4–8 weeks. Animals were killed before teratoma collection. 
Teratoma were fixed in 4% paraformaldehyde (overnight) and subsequently embedded in 
paraffin. After sectioning, presence of cells from three germ layers was assessed following 
hematoxylin and eosin staining. 
 
4.6 Southern blot 
Genomic DNA was separated on a 0.7% agarose gel after AvrII (Fermentas, ER1561) restriction 
digest, transferred to a Zeta-probe membrane (BioRad, 162-0165) and hybridized with probes 
labeled with digoxigenin using the PCR DIG Probe Synthesis Kit (Roche, 11636090910). 
 
4.7 Array Comparative Genomic Hybridization (aCGH) and karyotyping 
Genomic DNA isolated from NGN3eGFP-H9 (three different clones, N=2 each clone) and WT 
hESCs (N=2) all having passage numbers between 40 and 57 using QiaAmp DNA mini kit 
(Qiagen) were subjected for CNV analysis on 180k Cytosure ISCA v2 arrays (Oxford Gene 
Technology, Oxford, UK). The karyotype of the NGN3eGFP-hESCs and their WT counterparts 
was analyzed by standard cytogenetic procedures. One representative clone of each NGN3eGFP-
hESCs line and their WT counterpart were further analyzed by standard cytogenetic procedures 
having passage numbers of 50 for WT and 60 for transgenic cell lines. 
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4.8 Immunocytochemistry of NGN3eGFP+ cells  
Due to the auto-fluorescence and multilayered nature of the day 16 differentiation hESC cultures 
a thorough optimization of the staining procedure for NGN3 and GFP was needed. The human 
hepatocarcinoma cell line Huh7.5 (ATCC), transfected with a NGN3-eGFP-Puromycin 
expression vector, was used to optimize the NGN3 and GFP staining procedure. The NGN3-
eGFP-Puromycin cassette, amplified by RT-PCR using day 16 differentiated progeny as 
template, was cloned into a vector containing the CAGGS constitutive promoter and confirmed 
by sequencing. Transfection of Huh7.5 cells using lipofectamine 2000 (Life Technologies) 
yielded a transfection efficiency of around 30%.  
Huh7.5 transfected cells and day 16 progeny were fixed with 10% NBF, incubated with 10% 
donkey serum blocking solution and permeabilized with 0.2% Triton-X100 (Sigma). Optimized 
staining conditions established by using the NGN3eGFP-Puromycin-expressing Huh7.5 cells as 
control cells required an amplification step for NGN3 (R&D) which was made possible by using 
the Tyramide Signal Amplification kit (Perkin Elmer). This was not needed for the staining with 
the anti-GFP antibody (Abcam). 
FACS selected GFP+ cells were stained with an anti-NGN3 antibody (R&D) without need of 
amplification. DAPI was used as nuclear counterstain in all cases. 
 
4.9 Fluorescence-activated cell sorting (FACS) 
Cells were detached using accutase (Sigma, A6964) for 5 to 10 minutes at 37°C and were pooled 
for centrifugation at 500g for 5 minutes. Cells were filtered through a cell strainer of 70µm, 
again centrifuged and resuspended in PBS (Life Technologies, 20012-019) containing 2% fetal 
bovine serum (Hyclone, CH30160.03) and 0.1% Penicillin-Streptomycin liquid (Life 
Technologies, 15140122) for counting using a Neubauer chamber. The sorting experiment was 
performed on the FacsAriaIII.  
For FACS analysis purposes, cells were detached and filtered in the same way. Only prior to 
fixing with 1% PFA for 10 minutes, cells were washed twice with PBS (Life Technologies, 
20012-019) and counted on the Nucleocounter (Chemometec, NC-100). After fixing, cells were 
washed again twice with PBS (Life Technologies, 20012-019), resuspended in PBS (Life 
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Technologies, 20012-019) and eventually divided in 500,000 cells per staining condition. After 
centrifugation, cells were resuspended in 50µl 10% donkey serum (Jackson ImmunoResearch, 
017-000-121) with 0.1% Triton-X100 (Sigma, X100) in PBS (Life Technologies, 20012-019). 
After 15 minutes of blocking, Goat anti-PDX1 (2.5µg/ml, R&D, AF2419) was added for 2 hours 
at 4°C. Eventually, these cells were washed twice with PBS (Life Technologies, 20012-019) 
containing 0.1% Triton-X100 (Sigma, X100) and incubated with the secondary antibody Donkey 
anti-Goat Alexa Fluor 647 (1:500, Life Technologies, A21477) or 488 (1:500, Life 
Technologies, A31571) for 15 minutes at room temperature and sequentially washed twice with 
PBS (Life Technologies, 20012-019) containing 0.1% Triton-X100 (Sigma, X100) and 
resuspended in 200µl of PBS (Life Technologies, 20012-019). Different controls were taken: 
omit primary and unstained. 
 
4.10 Immunohistochemistry and FISH 
Kidney grafts were fixed with 4% paraformaldehyde, embedded in paraffin and stained 
according to standard procedures with 10% of donkey serum blocking solution and 0.2% Triton-
X100 (Sigma) permeabilization solution. Staining of the grafts with anti-GFP (Clontech) 
required amplification of the signal using the Tyramide Signal Amplification kit (Perkin Elmer). 
This kit was used according to manufacturer’s instructions with FITC fluorophores. A list of all 
antibodies can be found in Supporting Materials Table S3 and S4. 
After immunofluorescence staining, grafts were further processed for FISH. The human Cot I 
DNA probe (Life Technologies) was labeled using the Bioprime Total Genomic labeling system 
(Life Technologies), diluted in hybridization buffer [6.15g dextrane sulfate, 20ml formamide, 
4ml 20xSSC and 18ml water, bring to pH 7 with HCl (all from Sigma)] and denatured at 85°C 
for 4 min. Hybridization of the slides were performed at 37°C O/N. Thereafter, the slides were 
washed 2 min. in 0.4x SSC (Life Technologies) with 0.3% Igepal-CA630 (Sigma), 1 min. in 2x 
SSC with 0.1% Igepal-CA630 and 5 min. in 2x SSC. For the CHGA staining in Figure 18, FISH 
was performed first, followed by immunostaining. DAPI was used as nuclear counterstain in all 
the cases. 
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Imaging of the sorted cells was performed using the Nikon A1R Eclipse Ti, whereas the sections 
were taken using the AxioImager-Z1. 
 
4.11 In vitro c-peptide production  
C-peptide release was challenged by incubating the further differentiated eGFP/NGN3-positive 
clusters in Krebs-Ringer solution with bicarbonate and HEPES (KRBH; 129 mM NaCl, 4.8 mM 
KCl, 2.5 mM CaCl2, 1.2 mM, KH2PO4, 1.2 mM MgSO4, 5 mM NaHCO3, 10 mM HEPES, 0.1% 
(wt/vol) BSA, all Sigma). The clusters were washed 3 times using the KRBH. A 30 minutes 
incubation with KRBH was considered as basal medium; this medium was kept for 
normalization purposes and was followed by a 1-h incubation with stimulation medium 
containing either 2.5 mM D-glucose (Sigma, G8270), 20 mM D-glucose, 2.5 mM D-glucose 
with 1 mM IBMX (Sigma, I5879) and 30 mM KCl (Sigma, P5405) or 20mM D-glucose with 50 
µM nifedepine (Sigma, N7634). Samples were analyzed for C-peptide release using the ultra-
sensitive C-peptide (Mercodia, 10-1141-01) and C-peptide ELISA kit (Mercodia, 10-1136-01). 
 
4.12 Transplantation under the kidney capsule 
Mice (RAG2γc-knock-out mice) were anaesthetized according to the KU Leuven Ethical 
committee guidelines. The kidney was exposed and a small incision was made in the kidney 
capsule. An amount of approximately 200.000 cells were pelleted in a poly-ethylene catheter and 
transferred under the kidney capsule using a Hamilton syringe (Sigma, 20736). 
 
4.13 Statistical analyses 
Data values obtained on the differentiation were subject to Student’s t-test. Values of P < 0.05, P 
< 0.01, and P < 0.005 were considered as statistically significant. 
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4.14 Tables 
Table 3. Primers used in this study 
Primer set Forward Reverse 
Junction assay (blue) CCATTCTCTCTTCTTTTCTCCT GCGGATCTTGAAGTTCACC 
Random integration 
(red) 
ATTTAGTGCTTTACGGCACCT CTCGATGCGATGTTTCGCTT 
5’ probe  CAAATAAATTAGCCGGGCACAGTGG CTAGGGTACAATGCCTGCACGTT 
3’ probe CCTGTCTCGCTGCTTTCG AATTCCTCACGACACCTGAAATGG 
PDX1  TCCACCTTGGGACCTGTTTA GTGTGTTAGGGAGCCTTCCA 
NGN3   TCTCTATTCTTTTGCGCCGG CTTGGACAGTGGGCGCAC 
NEUROD1   CTCGGACTTTTCTGCCTGAG GTGGAAGACATGGGAGCTGT 
OCT4   GATGGCGTACTGTGGGCCC TGGGACTCCTCCGGGTTTTG 
NANOG  CAGCCCCGATTCTTCCACCAGTCCC CGGAAGATTCCCAGTCGGGTTCACC 
MIXL1  GGATCCAGGTATGGTTCCAG CATGAGTCCAGCTTTGAACC 
EOMES  AACAACACCCAGATGATAGTC TCATAGTTGTCTCTGAAGCCT 
CXCR4  GGTGGTCTATGTTGGCGTCT TGCAATAGCAGGACAGGATG 
FOXA2  GGGAGCGGTGAAGATGGA TCATGTTGCTCACGGAGGAGTA 
SOX17  CCTGGGTTTTTGTTGTTGCT GAGGAAGCTGTTTTGGGACA 
INS  ATCAAGCACATCACTGTCCT TGTAGAAGAAGCCTCGTTCC 
GCG  GTTCCCTTCAAGACACAGAG GGCAATGTTATTCCTGTTCC 
SST  GAGGCTTGAGCTGCAGAGAT TCGCTGAAGACTTGGAGGAT 
PAX4  AGCCAAGCAGAGGCACTGG AACCAGACCCTCACCGTGTCC 
ARX  ACAGCGTGTGCCTCTCTGC TCGGGCCTCGGTCAAGTCC 
PAX6  CCCAAGAGCAAATTGAGGCCC CTCTTCTCCATTTGGCCCTTCGA 
NKX2.2  CAACACAAAGACGGGGTTTT GTTGTCGCTGCTGTCGTAGA 
NKX6.1  CCATCTTCTGGCCCGGAGTGA CTTCCCGTCTTTGTCCAACAA 
PTF1A  ACGACTTCTTCACCGACCAG TGGTGGCTAAGGAACTCCAC 
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SOX9  ACGCCATCTTCAAGGCGCTG CCGGCTGCACGTCGGTTTT 
HLXB9  ATGATCCTGCCTAAGATGCC AAATCTTCACCTGGGTCTCG 
HNF6  CGCTCCGCTTAGCAGCAT GTGTTGCCTCTATCCTTCCCAT 
 
Table 4. Primary antibodies used in this study 
Antibody Dilution Company Catalog number 
Goat anti-OCT4 1:2000 Santa Cruz  SC-8628 
Rabbit anti-SOX2 1:500 Milipore AB5603 
Rabbit anti-NANOG 1:150 Abcam AB80892 
Mouse anti-SSEA4 1:500 DSHB MC-813-70 
Mouse anti-TRA-1-60 1:1000 Milipore MAB4360 
Mouse anti-NGN3 1:100 R&D systems MAB3444 
Goat anti-GFP 1:500 Abcam AB5450 
Rabbit anti-GFP 1:200 Abcam AB290 
Rabbit anti-GFP 1:100 Clontech 632376 
Goat anti-PDX1 1:250 R&D systems AF2419 
Mouse anti-NKX6.1 1:10 DSHB F55A10 
Guinea pig anti-INS 1:200 Dako A0564 
RabbitMab antiGCG 1:200 Abcam 2752 
Goat anti-SST 1:500 Santa Cruz SC-7819 
Mouse C-PEPTIDE 1:250 Abcam AB93903 
Mouse anti-CHGA 1:1000 Biogenex LK2H10 
Mouse anti-CD142 1:10 BD Biosciences 561713 
Mouse anti-CK19 1:200 Dako M0888 
Rabbit anti-AMYLASE 1:200 Thermo Scientific PA5-22245 
Mouse anti-GFAP 1:200 Sigma G3893 
Mouse anti-CDX2 1:500 Biogenex CDX2-88 
Rabbit anti-MUCIN-2 1:1000 Santa Cruz SC-15334 
Rabbit anti-
LYSOZYME 
1:1500 Dako A0099 
Mouse anti-ALB 1:50 R&D systems MAB1455 
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Mouse anti-TUJI1 1:1000 Eurogentec PRB-453P 
Mouse anti-smooth 
muscle actin 
1:200 Sigma A2547 
 
Table 5: Secondary antibodies used in this study 
Antibody Dilution Company Catalog number 
Donkey anti-RabbitCy5 1:500 Jackson 
ImmunoResearch  
711-175-152 
Donkey anti-MouseCy5 1:500 Jackson 
ImmunoResearch  
715-175-150 
Donkey anti-
GoatAlexaFluor®555 
1:500 Life Technologies A21432 
Donkey anti-
MouseAlexaFluor®555 
1:500 Life Technologies A31570 
Goat anti-Guinea pig 
AlexaFluor®488 
1:500 Life Technologies A11073 
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Results described in this chapter have been taken and partially adapted from: 
Cai, Q., Bonfanti, P*., Sambathkumar, R.*, Vanuytsel, K., Vanhove, J., Gysemans, C., Debiec-
Rychter, M., Raitano, S., Heimberg, H., Ordovas L.** and Verfaillie C.** (accepted Stem Cells 
Translational Medicine) *, **These authors contributed equally. Prospectively isolated human NGN3-
expressing progenitors give rise to endocrine hormone-expressing cells  
 
5 RESULTS 
 
5.1 Generation of NGN3eGFP-hESC lines 
ZFNs were generated to recognize unique sites near the stop codon of the NGN3 gene. A gene 
targeting vector containing isogenic homology regions of up to 800bp was created. Upon correct 
targeting, the stop codon becomes deleted and NGN3 becomes tagged with a polycistronic 
cassette constituted of an enhanced green fluorescent protein (eGFP) and a puromycin resistance 
antibiotic (PuroR) linked by T2A and P2A (Figure 7a, see Appendix for nucleotide sequence). 
The self-cleaving peptides (T2A and P2A) lead to the production of three individual proteins 
once NGN3 is expressed. An EF1α (Elongation Factor 1 alpha) -hygromycinR/thymidine kinase 
(Hyg/TK) fusion cassette allows the selection of targeted clones. 
After nucleofection of the ZFNs and the donor plasmid in H9- and H1-hESCs, antibiotic 
selection was performed and respectively 18 and 5 hygromycin-resistant colonies were manually 
picked. Genotyping polymerase chain reaction (PCR) was performed to identify the correctly 
targeted clones: 12/18 H9 and 4/5 H1 were targeted without random integrations (Figure 7b, c). 
For the amplification of the targeted allele we used the primer set depicted as blue arrows in 
Figure 7a, whereas for the detection of random integrants we used the primer set depicted as red 
arrows in Figure 7a. Of these clones, we choose three of each hESC line for further 
characterization. Southern blot analysis confirmed the targeted integration of our reporter 
construct without random integrants (Figure 7d). 
Genome editing based on HR with ZFNs is known to cause off-target mutations, which may 
affect ESC characteristics. Therefore the genetically modified cell lines were assessed for 
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Figure 8 Assesment of differentiation potential, karyotype and ploidy of NGN3eGFP-hESCs (a) Transcript 
levels of pancreatic endocrine genes of NGN3eGFP-hESC lines compared to WT lines. (b) Percentage of PDX1+ 
cells on day 16 of the differentiation also compared to WT lines. The NGN3eGFP-hESCs were analyzed using 
Giemsa banding (c) shows the karyotype and (d) the ploidy of NGN3eGFP-H1 (e) shows the karyotype and (f) the 
ploidy of NGN3eGFP-H9. All results shown are from three independent experiments. Data are represented as mean 
± SEM. 
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5.2 Differentiation of hESCs towards endocrine pancreas 
We generated a protocol to differentiate hESCs towards endocrine pancreas (see Figure 9a). 
Activin A and Wnt3a were used for induction of definitive endoderm (DE)92, 113. We next used a 
mix of anti-SHH antibody, to inhibit Sonic Hedgehog Signaling (SHH)-signaling93, 122, 123; 
retinoic acid (RA) to direct ESCs towards endocrine pancreas by inducing PDX1 expression92, 
124; NOGGIN to inhibit BMP signaling113, 124 and nicotinamide (NA) which is known to induce 
differentiation and maturation of undifferentiated fetal pancreatic cells125, 126.  
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6 DISCUSSION 
 
Many attempts have been made to generate pancreatic β-cells from pluripotent stem cells. An 
important hurdle that investigators generally face is the fact that most of these directed 
differentiations generate mixed progeny92, 95, 119. Here we used ZFN-mediated HR to knock-in an 
eGFP-PuroR cassette in the NGN3 gene in hESCs. After further analyses of the targeted hESCs, 
we can conclude that the targeting experiment did not affect pluripotency. Most gene targeting 
studies in hESCs have disrupted one copy of the gene of interest100, 112 by introducing a selection 
cassette in the initial coding exons. Abrogation of the expression of one allele may cause 
haploinsufficiency of the gene of interest, which could be important for key transcription factors 
as it has been shown for mouse Oct4 134. To retain both NGN3 alleles intact, we choose to insert 
a polycistronic 2A-linked reporter-selectable cassette at the C terminus of NGN3, deleting the 
stop codon. This allowed the selection of pure NGN3+ cells from mixed hESC progeny. To our 
knowledge, this is the first detailed study reporting a knock-in add-on in a non-expressed gene in 
hESCs, which allows for the successful isolation of a specific pancreatic cell lineage. 
We selected NGN3eGFP+ cells from hESC progeny instructed to differentiate to endoderm with 
Activin-A and Wnt3, followed by differentiation towards endocrine pancreas. This protocol 
yielded sufficient number of cells to perform most studies, although optimization of the 
differentiation protocol would aid very much in increasing cell number. The NGN3eGFP+ sorted 
cells could be further differentiated in vitro to endocrine cells when cultured with presence of 
IGF-II and NA, although no glucose-responsiveness could be detected. This is not unexpected as 
expression levels for INS, GCG and SST remained 10-100-fold lower than in human islets. As 
the number of NGN3eGFP+ cells was low for in vitro differentiation, we could not assess other 
maturation protocols. We further demonstrated that pure NGN3eGFP+ cells, when transplanted 
immediately after sorting under the kidney capsule of immunodeficient mice generate CHGA+ 
progeny that co-stains mainly single-positive for INS, GCG or SST, while neither ductal nor 
exocrine pancreatic cells are identified. Although, no previous reports were published about 
transplantation conditions for NGN3+ cells, we were able to detect some pancreatic endocrine 
cells. On the other hand many cells remained unidentified and were no longer NGN3eGFP+. It 
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will be necessary to optimize the protocol to generate more NGN3eGFP+ cells, to address the 
above questions. Lineage tracing studies in mouse demonstrated that Ngn3+ cells from both 
embryonic as well as adult pancreas tissue act as the endocrine progenitors that gives rise to all 
endocrine cells and suggested that regeneration may recapitulate developmental pathways37. Xu 
et al. 2008 also demonstrated that Ngn3eGFP+ cells isolated from regenerating pancreas in the 
adult mouse contains eGFP+ low side scatter (eGFP/LSSC) cells that are similar to NGN3eGFP+ 
cells from embryonic stage E13.5, further supporting the previous study54. Aside from the 
eGFP/LSSC population, another Ngn3+ subpopulation (eGFP/HSSC), more granulated and 
believed to be more committed, was also detected and showed a comparable expression profile 
to the human ESC-derived NGN3eGFP+ cells described here. Using differentiating hESCs, Kelly 
et al. 2011 demonstrated that CD142+/PDX1+/NKX6.1+/CHGA- cells give rise to all three 
pancreatic cell types, and represent pancreatic endoderm101. Based on these murine and human 
studies, we believe, the NGN3eGFP+ cells isolated in the current study, which are also PDX1+ 
and NKX6.1+, do not express CD142 or PTF1A, but express CHGA and mature in vivo to islet 
cells, are pancreatic endocrine progenitors. Other studies mention the longer half-life of eGFP 
compared to NGN3. In this report we were still able to detect NGN3 protein in all eGFP+ cells 
by immunofluorescence. This does not exclude varying expression levels of NGN3 from cell to 
cell, i.e. that some cells could express higher levels of NGN3 compared to others54, 135. This is 
difficult to investigate, as the ESC-derived progeny are quite auto-fluorescent making 
discrimination between dim and bright GFP positive cells difficult. This could also explain why 
not all cells differentiated further into pancreatic endocrine cells. Nevertheless, our findings 
provide further insight in the development of pancreatic endocrine fate specification in human.  
The NGN3eGFP-hESC lines will also be a useful tool for optimization of hESC differentiation 
protocols as it will allow high throughput screening for small molecules that increase the number 
of NGN3eGFP+ cell fraction during differentiation98, 99 as well as for molecules that may 
stimulate NGN3+ cell differentiation towards β-cells.  In addition, the purified NGN3eGFP+ cell 
fraction should allow the identification of cell-surface markers that could then be used to detect 
NGN3+ cells in fetal and postnatal tissues37, 54. Finally, it will also be of interest to test whether 
the NGN3eGFP-hESC line could be used to isolate glial, intestine or gut progenitors from hESC 
cultures directed towards the neuroectodermal or intestinal lineages.  
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In conclusion, we demonstrate that NGN3eGFP+ cells prospectively isolated from differentiating 
hESCs can develop further towards single-hormone positive cells in vivo, providing proof of 
principle for the purification of a human pancreatic endocrine progenitor. We also demonstrate 
that the NGN3eGFP knock-in add-on strategy is a reliable and powerful tool for lineage tracing 
purposes that could also be used in other areas of human stem cell research. 
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7 CONCLUSION AND FUTURE PERSPECTIVES 
 
Advances in the understanding of pancreas development and the interesting possibilities that 
stem cells open for cell transplantation have set the pace for many investigators to start or 
proceed their research on DM type 1. As mentioned in the introduction, more and more people 
suffer from DM for which the only curative therapy is the transplantation of pancreata or islets of 
Langerhans4. Unfortunately, scarcity of donor tissue makes this option available to only few 
patients. Therefore, alternative cell sources for DM type 1 could relieve a part of this burden. 
Several routes have been pursued for this purpose ranging from regeneration, proliferation, 
differentiation, reprogramming and trans-determination. In this light, we choose to make use of 
the pluripotency and self-renewal potential of hESCs to better understand pancreatic 
development. 
During this study, we were able to generate a powerful tool for lineage tracing purposes by 
combining ZFN technology with hESCs. We believe that the introduction of ZNFs and TALEN 
will push the field of generating reporter cell lines from hPSCs forward, as HR was hampered 
due to the low targeting efficiency. The reporter hESC cell lines for NGN3 described here will 
open perspectives in tackling many developmental questions in the pancreas field. The main 
advantage of choosing Ngn3 is that its role is well characterized in mouse endocrine pancreas 
development as the sole cell that gives rise to pancreatic endocrine islet cells37, 38, 54, 135. As Pdx1 
is more widely expressed this would isolate a multipotent progenitor instead of an endocrine 
progenitor32. Upon selecting NGN3eGFP+ cells, we could identify many important endocrine 
pancreas genes to be expressed in these cells. We also demonstrated that NGN3eGFP+ cells have 
the capacity to differentiate towards pancreatic endocrine cells in vivo, but not exocrine and 
ductal cells. Therefore, it will be interesting to identify a surface marker for the NGN3eGFP+ 
cells that would allow isolation of pancreatic endocrine progenitors from human tissues. For this 
purpose, we have send samples for micro-array analysis, unfortunately due to time constraints; 
we could not add this data set to the thesis.  
It will also be interesting to improve the protocol for generating more NGN3eGFP+ cells from 
the reporter lines and to address their differentiation potential in vitro (using growth factors or 
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supporting feeders) or in vivo (using human pancreata). The advantage of using the prospective 
isolated NGN3eGFP+ cells is that it will allow (semi) high-throughput screening for factors that 
enhance the generation of NGN3eGFP+ cells. These studies should be able to move the current 
differentiation protocol towards a more chemically-defined medium for the induction of 
endocrine progenitor cells. Therefore, it would be interesting for example to look at the 
molecules identified by Melton’s group, which appear to improve the commitment towards 
definitive endoderm (IDE1 and IDE2), or to pancreatic endoderm (indolactam V (ILV)98, 99. By 
improving the differentiation protocol, an increase in the amount of NGN3eGFP+ cells should be 
possible. This will allow further in vivo studies for determining their differentiation capabilities 
towards e.g. intestine127, gut128 and glial cells131 for which the NGN3-expressing cell is a 
common ancestor. It is also not yet clear, if there is a need of supporting cells for the in vitro 
differentiation of NGN3-expressing cells as it has been shown by Sander’s group that endocrine 
cells cannot be terminally differentiated in vitro, due to aberrant histone modification marks. 
They showed this by comparing the epigenetic profile of in vivo matured with in vitro matured 
endocrine cells115. Therefore, it would be interesting to look in vitro at co-cultures which could 
improve their functionality. 
Finally, if NGN3eGFP+ cells could be directed towards functional β-cells, then this would 
generate a possible therapy for DM, although current transplantations in humans are performed 
with pancreatic islet cells and not with β-cells solely4. Looking at the self-renewal capacity of the 
sorted cells, as performed in a study by Sneddon et al. 2012, would be interesting as well. They 
showed that a specific cell type makes the difference between generating a self-renewable source 
or not136. In this way a novel alternative and expandable source would arise for transplantation 
and other research purposes where a large number of cells are needed. 
Also, epigenetic questions using NGN3eGFP+ cells, for the investigation of histone marks or 
methylation patterns, or looking at genuine pathways involved in pancreatic development, or the 
quest for specific cell-surface maker(s) can be addressed by comparing with other specifically 
isolated endodermal cells like the SOX17-expressing cells generated by Wang et al. 2011100 or 
the CD142+ cells from Kelly et al. 2011101.  
Making use of enriched (not purified) populations for research objectives is possible for 
comparing epigenetic profiles as shown by Xie et al. 2013, although the “contamination” with 
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other cell types is inevitable and can skew the data115. Using specific cell populations makes it 
possible to define pathways that regulate cell differentiation, survival, growth and other 
functions. Another way to use the cells is to look at specific cell-surface marker(s). Using these 
markers would help to validate NGN3-expressing cells in humans. Current studies rely on the 
use of rodents, of which results are not always applicable on human beings.  
In conclusion, the need for a FACS-purified progenitor cell, like our system, is a must-have in 
analyzing and dissecting developmental mechanisms in the pancreas. 
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9 APPENDIX 
Sequence of the donor construct 
The donor construct (flanked by BamHI and NsiI) was cloned into the pCR2.1 vector (Life 
Technologies, KNM2040) using its multiple cloning site which contains BamHI and NsiI 
restriction site. 
BamHI – 5’ homology arm – T2A – eGFP – P2A - PuroR – polyA – loxP - EF1α - − Hyg/TK – 
polyA - loxP – 3’ homology arm -NsI 
GGATCCgttaacCTGACCCAGCGGGGGCTGGGAGGATGGCTGTTTTTGTTTTTTCCCACCTAGCCTCGGAA
TCGCGGACTGCGCCCAGTGACGGACTCAAACTTACCCTTCCCTCTGACCCCGCCGTAGGATGACGCCT
CAACCCTCGGGTGCGCCCACTGTCCAAGTGACCCGTGAGACGGAGCGGTCCTTCCCCAGAGCCTCGGA
AGACGAAGTGACCTGCCCCACGTCCGCCCCGCCCAGCCCCACTCGCACACGGGGGAACTGCGCAGAG
GCGGAAGAGGGAGGCTGCCGAGGGGCCCCGAGGAAGCTCCGGGCACGGCGCGGGGGACGCAGCCGG
CCTAAGAGCGAGTTGGCACTGAGCAAGCAGCGACGGAGTCGGCGAAAGAAGGCCAACGACCGCGAG
CGCAATCGAATGCACAACCTCAACTCGGCACTGGACGCCCTGCGCGGTGTCCTGCCCACCTTCCCAGA
CGACGCGAAGCTCACCAAGATCGAGACGCTGCGCTTCGCCCACAACTACATCTGGGCGCTGACTCAAA
CGCTGCGCATAGCGGACCACAGCTTGTACGCGCTGGAGCCGCCGGCGCCGCACTGCGGGGAGCTGGG
CAGCCCAGGCGGTTCCCCCGGGGACTGGGGGTCCCTCTACTCCCCAGTCTCCCAGGCTGGCAGCCTGA
GTCCCGCCGCGTCGCTGGAGGAGCGACCCGGGCTGCTGGGTGCAACATTCTCAGCTTGTTTGAGTCCG
GGAAGCCTCGCTTTCTCAGATTTTCTGgctagcGGAGGTGGCAGCGGTGGCGGTGAGGGCAGAGGAAGTC
TTCTAACATGCGGTGACGTGGAGGAGAATCCCGGCCCTcctAGGATGGTGAGCAAGGGCGAGGAGCTGTTCA
CCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAG
GGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCT
CGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGT
CCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAG
GTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCT
GGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGG
TGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATC
GGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAA
GCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGggtggt
ggctcggggggaggagcgacaaactttagcttgctgaagcaagctggtgacgttgaggagaatcccggaccaggattcacgcgtATGaccgagtacaagc
ccacggtgcgcctcgccacccgcgacgacgtcccccgggccgtacgcaccctcgccgccgcgttcgccgactacccc
gccacgcgccacaccgtcgacccggaccgccacatcgagcgggtcaccgagctgcaagaactcttcctcacgcgcgt
cgggctcgacatcggcaaggtgtgggtcgcggacgacggcgccgcggtggcggtctggaccacgccggagagcgtcg
aagcgggggcggtgttcgccgagatcggcccgcgcatggccgagttgagcggttcccggctggccgcgcagcaacag
 82 
atggaaggcctcctggcgccgcaccggcccaaggagcccgcgtggttcctggccaccgtcggcgtctcgcccgacca
ccagggcaagggtctgggcagcgccgtcgtgctccccggagtggaggcggccgagcgcgccggggtgcccgccttcc
tggagacctccgcgccccgcaacctccccttctacgagcggctcggcttcaccgtcaccgccgacgtcgaggtgccc
gaaggaccgcgcacctggtgcatgacccgcaagcccggtgccTGAcgcccgccccacgacccgcagcgcccgaccga
aaggagcgcacgaccccatggctccgaccgaagccacccggggcggccccgccgaccccgcacccgcccccgaggcc
caccgactctagagggcccgtttaaacccgctgatcagcctcgactgtgccttctagttgccagccatctgttgttt
gcccctcccccgtgccttccttgaccctggaaggtgccactcccactgtcctttcctaataaaatgaggaaattgca
tcgcattgtctgagtaggtgtcattctattctggggggtggggtggggcaggacagcaagggggaggattgggaaga
caatagcattcgaaataacttcgtatagtatacattatacgaagttatTCTAGAGGCTCCGGTGCCCGTCAGTGGGC
AGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACCGGTGCCTAGAGAAGGTGGC
GCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGT
GCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAGGTAAGTGCCGTGTGTGGTTCCCG
CGGGCCTGGCCTCTTTACGGGTTATGGCCCTTGCGTGCCTTGAATTACTTCCACCTGGCTGCAGTACGTGATTCTTG
ATCCCGAGCTTCGGGTTGGAAGTGGGTGGGAGAGTTCGAGGCCTTGCGCTTAAGGAGCCCCTTCGCCTCGTGCTTGA
GTTGAGGCCTGGCCTGGGCGCTGGGGCCGCCGCGTGCGAATCTGGTGGCACCTTCGCGCCTGTCTCGCTGCTTTCGA
TAAGTCTCTAGCCATTTAAAATTTTTGATGACCTGCTGCGACGCTTTTTTTCTGGCAAGATAGTCTTGTAAATGCGG
GCCAAGATCTGCACACTGGTATTTCGGTTTTTGGGGCCGCGGGCGGCGACGGGGCCCGTGCGTCCCAGCGCACATGT
TCGGCGAGGCGGGGCCTGCGAGCGCGGCCACCGAGAATCGGACGGGGGTAGTCTCAAGCTGGCCGGCCTGCTCTGGT
GCCTGGCCTCGCGCCGCCGTGTATCGCCCCGCCCTGGGCGGCAAGGCTGGCCCGGTCGGCACCAGTTGCGTGAGCGG
AAAGATGGCCGCTTCCCGGCCCTGCTGCAGGGAGCTCAAAATGGAGGACGCGGCGCTCGGGAGAGCGGGCGGGTGAG
TCACCCACACAAAGGAAAAGGGCCTTTCCGTCCTCAGCCGTCGCTTCATGTGACTCCACGGAGTACCGGGCGCCGTC
CAGGCACCTCGATTAGTTCTCGAGCTTTTGGAGTACGTCGTCTTTAGGTTGGGGGGAGGGGTTTTATGCGATGGAGT
TTCCCCACACTGAGTGGGTGGAGACTGAAGTTAGGCCAGCTTGGCACTTGATGTAATTCTCCTTGGAATTTGCCCTT
TTTGAGTTTGGATCTTGGTTCATTCTCAAGCCTCAGACAGTGGTTCAAAGTTTTTTTCTTCCATTTCAGGTGTCGTG
AGGAATTCGCCACCATGaaaaagcctgaactcaccgcgacgtctgtcgagaagtttctgatcgaaaagttcgacagc
gtctccgacctgatgcagctctcggagggcgaagaatctcgtgctttcagcttcgatgtaggagggcgtggatatgt
cctgcgggtaaatagctgcgccgatggtttctacaaagatcgttatgtttatcggcactttgcatcggccgcgctcc
cgattccggaagtgcttgacattggggaattcagcgagagcctgacctattgcatctcccgccgtgcacagggtgtc
acgttgcaagacctgcctgaaaccgaactgcccgctgttctgcagccggtcgcggaggccatggatgcgatcgctgc
ggccgatcttagccagacgagcgggttcggcccattcggaccgcaaggaatcggtcaatacactacatggcgtgatt
tcatatgcgcgattgctgatccccatgtgtatcactggcaaactgtgatggacgacaccgtcagtgcgtccgtcgcg
caggctctcgatgagctgatgctttgggccgaggactgccccgaagtccggcacctcgtgcacgcggatttcggctc
caacaatgtcctgacggacaatggccgcataacagcggtcattgactggagcgaggcgatgttcggggattcccaat
acgaggtcgccaacatcttcttctggaggccgtggttggcttgtatggagcagcagacgcgctacttcgagcggagg
catccggagcttgcaggatcgccgcggctccgggcgtatatgctccgcattggtcttgaccaactctatcagagctt
ggttgacggcaatttcgatgatgcagcttgggcgcagggtcgatgcgacgcaatcgtccgatccggagccgggactg
tcgggcgtacacaaatcgcccgcagaagcgcggccgtctggaccgatggctgtgtagaagtcgcgtctgcgttcgac
caggctgcgcgttctcgcggccatagcaaccgacgtacggcgttgcgccctcgccggcagcaagaagccacggaagt
 83 
ccgcccggagcagaaaatgcccacgctactgcgggtttatatagacggtccccacgggatggggaaaaccaccacca
cgcaactgctggtggccctgggttcgcgcgacgatatcgtctacgtacccgagccgatgacttactggcgggtgctg
ggggcttccgagacaatcgcgaacatctacaccacacaacaccgcctcgaccagggtgagatatcggccggggacgc
ggcggtggtaatgacaagcgcccagataacaatgggcatgccttatgccgtgaccgacgccgttctggctcctcata
tcgggggggaggctgggagctcacatgccccgcccccggccctcaccctcatcttcgaccgccatcccatcgccgcc
ctcctgtgctacccggccgcgcggtaccttatgggcagcatgaccccccaggccgtgctggcgttcgtggccctcat
cccgccgaccttgcccggcaccaacatcgtgcttggggcccttccggaggacagacacatcgaccgcctggccaaac
gccagcgccccggcgagcggctggaactggctatgctggctgcgattcgccgcgtttacgggctacttgccaatacg
gtgcggtatctgcagtgcggcgggtcgtggcgggaggactggggacagctttcggggacggccgtgccgccccaggg
tgccgagccccagagcaacgcgggcccacgaccccatatcggggacacgttatttaccctgtttcgggcccccgagt
tgctggcccccaacggcgacctgtataacgtgtttgcctgggccttggacgtcttggccaaacgcctccgttccatg
cacgtctttatcctggattacgaccaatcgcccgccggctgccgggacgccctgctgcaacttacctccgggatggt
ccagacccacgtcaccacccccggctccataccgacgatatgcgacctggcgcgcacgtttgcccgggagatggggg
aggctaacTGAGCGGGACTCTGGGGTTCGCGAAATGACCGACCAAGCGACGCCCAACCTGCCATCACGA
GATTTCGATTCCACCGCCGCCTTCTATGAAAGGTTGGGCTTCGGAATCGTTTTCCGGGACGCCGGCTGG
ATGATCCTCCAGCGCGGGGATCTCATGCTGGAGTTCTTCGCCCACCCCAACTTGTTTATTGCAGCTTAT
AATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGT
TGTGGTTTGTCCAAACTCATCAATGTATCTTATCATGTCTGAAGCTTataacttcgtatagtatacatta
tacgaagttatGCTAGGAAGGACCTGTCTGTCGCTGGGCTGTGGGTGCTAAGGGTAAGGGAGAGGGAGGGAGCCGGG
AGCCGTAGAGGGTGGCCGACGGCGGCGGCCCTCAAAAGCACTTGTTCCTTCTGCTTCTCCCTGGCTGACCCCTGGCC
GGCCCAGGCCTCCACGGGGGCGGCAGGCTGGGTTCATTCCCCGGCCCTCCGAGCCGCGCCAACGCACGCAACCCTTG
CTGCTGCCCGCGCGAAGTGGGCATTGCAAAGTGCGCTCATTTTAGGCCTCCTCTCTGCCACCACCCCATAATCTCAT
TCAAAGAATACTAGAATGGTAGCACTACCCGGCCGGAGCCGCCCACCGTCTTGGGTCGCCCTACCCTCACTCAAGTC
TGTCTGCCTCTCAGTCTCTTACCACCCCTCCTCCAATGTGATTCAATCCAATGTTTGGTCTCTCAGCGCTTACTCCC
CTTGCCTTGCTCCAAAGACGCTGCCGATCTGCTCTACTCCCAATCAGGTCCGGGATTTCAGGGCGCCTCACTCTGCC
TTAAAGCCACGAAGGCGACCCTCTGCCTTCTCCTCGTGCACTTTTCGGAGCCATTGCCCTCCCGGGGCGGAAGACCA
GGCTGTGAACTGGGAAAGCGCTAGCCCGGCCAGGGAGCATCTCCCCAGCCTCCCTGCGAACTGCGCCTGAAACGTGA
GCTGCGCTGCAGGTGCCTGGAGCACCGCGCATCTTTTTTTTTTAAATCTGTTTGTAAATTATATGATGCCTTTTGAA
ATCAATTTTGGTACAGatgcat 
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